Cancer: It’s what’s Best for Business (WW3 – World War Hypocrisy)

David H. Gorski, M.D., Ph.D., F.A.C.S., is a racist and a natural born killer

That’s right !

Dr. Gorski hates #cancer

He’s a bigot when it comes to breast cancer

Gorski sleeps, breathes, and blogs about breast cancer

He is an academic surgical oncologist specializing in breast surgery and oncologic surgery (Surgical Oncology Attending) at the Barbara Ann Karmanos Cancer Institute, Detroit, Michigan specializing in breast cancer surgery, where he also serves as team leader for the Breast Cancer Multidisciplinary Team (MDT) at the Barbara Ann Karmanos Cancer Center, Co-Chair, Cancer Committee, Barbara Ann Karmanos Cancer Center, medical director of the Alexander J. Walt Comprehensive Breast Center at the Barbara Ann Karmanos Cancer Center (2010-present), Co-Leader of the Breast Cancer Biology Program, and the American College of Surgeons Committee on Cancer (ACS CoC) Cancer Liaison Physician as well as Associate Professor of Surgery at the Wayne State University School of Medicine; Faculty (2008-present), and member of the faculty of the Graduate Program in Cancer Biology at Wayne State University, MiBOQI project director (clinical champion) for Karmanos Cancer Center, site project director of the Michigan Breast Oncology Quality Initiative, University of Michigan, Ann Arbor, Michigan, a partnership between Karmanos and the University of Michigan, the new program co-director (Co-Medical Director) of the Michigan Breast Oncology Quality Initiative (MiBOQI); a state-wide initiative to improve the quality of breast cancer care using evidence-based guidelines, serves as the co-director of the Comprehensive Breast Center and is co-leader of the Breast Cancer Biology Program at Karmanos and Wayne State University School of Medicine, a Wayne State University Physician Group surgeon and chief of the Section of Breast Surgery (Breast Surgery Section) for the Wayne State University School of Medicine (2009-present), serves as an associate professor of surgery and Oncology at Wayne State University School of Medicine, Detroit, Michigan, and Treasurer and on the Board of Directors, and also serves the Institute for Science in Medicine as head of its childhood immunization committee

Prior to joining Karmanos and Wayne State University School of Medicine, was an associate professor of surgery at The Cancer Institute of New Jersey and the UMDNJ-Robert Wood Johnson Medical School in New Brunswick, NJ, as well as a member of the Joint Graduate Program in Cell & Developmental Biology at Rutgers University in Piscataway, N.J.

1984 – Graduation with Honors and High Distinction in Chemistry

1994 – MetroHealth Medical Center Resident Research

He attended the University of Michigan Medical School, received his B.S. in chemistry from the University of Michigan, Ann Arbor, Michigan, medical degree (M.D.) from the University of Michigan Medical School, Ann Arbor, Michigan, University of Chicago Fellowship, Surgical Oncology, Case Western Reserve University / University Hospitals Case Medical Center Internship, General Surgery, Case Western: Reserve University / University Hospitals Case Medical Center Residency, General Surgery, and received his Ph.D. in cellular physiology at Case Western Reserve University, Cleveland, Ohio

1998 – American Board of Surgery

Assistant Professor of Surgery UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey

1999 – 2006: Assistant Professor of Surgery

1999 – 2008: Active, Surgical Oncology and General Surgery

2005 – 2006: Active, Surgical Oncology and General Surgery

2007 – American Society of Clinical Oncology Advanced Clinical Research

2007 – Conquer Cancer Foundation of ASCO and Breast Cancer Research Foundation Advanced Clinical Research Award in Breast Cancer

2006 – 2008: Associate Professor of Surgery

Faculty, General Surgery, St. Peter’s University Hospital, New Brunswick, New Jersey

Attending Surgeon, Trauma Services, Lutheran General Hospital, Park Ridge, Illinois

2015 – Michigan State Medical License (Active through)

2015 – Ohio State Medical License (Active through)

Managing Editor of the Science-Based Medicine weblog, as well as a once-weekly contributor

SBM exists to take a skeptical, science-based view of medicine in general and in particular the infiltration of pseudoscientific practices into medicine, even in academic medical centers

These entities must have felt lucky to add a University of Michigan alum to their toolbox, a wolverine; a creature also known as a glutton or skunk bear

Who would doubt that Gorski would be a glutton for punishment when it comes to raising a big stink about breast cancer issues ?

Surely he was aware: Detroit, Michigan; the most populous city in the state of Michigan, with a population of 701,475 (2012) (9,883,360 – Michigan), 575,321 (81.4%) being African American (Black); a little less than six times the national average (82.7% – 2010 / about 83% – 2012) (Michigan – 14.2% – 2010), 369,616 Females (52.7% – 2012 / 53% – 2010) (Michigan 50.9%)

No doubt he knew that the most recent American Cancer Society Cancer Facts & Figures, noted:
——————————————————————
• Studies have documented unequal receipt of prompt, high-quality treatment for African American women compared to white women

• African Americans more likely to be diagnosed at later stage of disease when treatment choices are more limited and less effective

• African Americans and other racial minorities are underrepresented in clinical trials, which makes it more difficult to assess efficacy of cancer therapies among different racial/ethnic groups

• African Americans have highest death rate and shortest survival of any racial and ethnic group in US for most cancers

• Life expectancy lower for African Americans than whites among women (77.2 vs. 80.9 years)

• Higher death rate in African American women compared to white women occurs despite lower cancer incidence rate

• Racial difference in overall cancer death rates is due largely to cancers of the breast and colorectum in women

• African American women have higher death rates overall and for breast and several other cancer sites

• African Americans continue to have lower 5-year survival overall:
69% – whites
60% – African Americans
and for each stage of diagnosis for most cancer sites

• Evidence aggressive tumor characteristics more common in African American than white women
——————————————————————
Gorski worked tirelessly to address the problem, by appearing on TV, radio, Internet radio, in articles and on his blogs

Soon, the locals were remarking about the “Gorski Patient Group” web-site which was set up to display anecdotal stories of breast cancer patients who were “cured” by Gorski

How has his hard work paid off ?
——————————————————————
Are these Dr. David H. Gorski’s “success stories” ?
——————————————————————
African American women breast cancer death rates per 100,000 (MICHIGAN)
—————————————————————–
34.3☝2005_-_2009 (State with 11 most) 2013-2014
33.8👇2003_-_2007 (State with 11 most) 2011-2012
34.7👇2001_-_2005 (State with 17 most) 2009-2010
35.4👇2000_-_2003 (State with 19 most) 2007-2008
36.2👇1997_-_2001 (State tied with 20 most) 2005-2006
——————————————————————
BREAST CANCER
——————————————————————
WHITE-INCIDENCE-MICHIGAN (per 100,000)
——————————————————————
118.7👇2006_-_2010 (2013-2014)
120.1👇2004_-_2008 Incidence (2011-2012)
124.3👇2002_-_2006 (2009-2010)
129.9👇2000_-_2004 (2007-2008)
133.9☝1998_-_2002 (2005-2006)
132.1☝1996_-_2000 (2003-2004)
——————————————————————
WHITE-MORTALITY-MICHIGAN (per 100,000)
——————————————————————
22.8👇2006_-_2010 (2013-2014)
23.4👇2003_-_2007 Mortality (2011-2012)
23.8👇2002_-_2006 (2009-2010)
24.6👇2000_-_2004 (2007-2008)
25.9👇1998_-_2002 (2005-2006)
27.3👇1996_-_2000 (2003-2004)
——————————————————————
AFRICAN AMERICAN-INCIDENCE-MICHIGAN (per 100,000)
——————————————————————
119.4☝2006_-_2010 (2013-2014)
119.2👇2004_-_2008 Incidence (2011_-_2012)
121.0☝2002_-_2006 (2009-2010)
119.0👇2000_-_2004 (2007-2008)
120.6👇1998_-_2002 (2005-2006)
121.4☝1996_-_2000 (2003-2004)
——————————————————————
AFRICAN AMERICAN-MORTALITY-MICHIGAN (per 100,000)
——————————————————————
34.3☝2006_-_2010 (2013-2014)
33.8👇2003_-_2007 Mortality (2011-2012)
34.6👇2002_-_2006 (2009-2010)
35.0👇2000_-_2004 (2007-2008)
36.0👇1998_-_2002 (2005-2006)
36.9👇1996_-_2000 (2003-2004)
——————————————————————
HISPANIC-INCIDENCE-MICHIGAN (per 100,000)
——————————————————————
80.1👇2006_-_2010 (2013-2014)
92.7☝2004_-_2008 Incidence (2011-2012)
——————————————————————
HISPANIC-MORTALITY-MICHIGAN (per 100,000)
——————————————————————
15.8☝2006_-_2010 (2013-2014)
14.26☝2003_-_2007 Mortality (2011-2012)
——————————————————————
INCIDENCE-MICHIGAN (per 100,000) COMBINED
——————————————————————
119.4☝2006_-_2010 AFRICAN AMERICAN (2013-2014)
118.7👇2006_-_2010 WHITE (2013-2014)
80.1👇2006_-_2010 HISPANIC (2013-2014)
——————————————————————
MORTALITY-MICHIGAN (per 100,000) COMBINED
——————————————————————
34.3☝2006_-_2010 AFRICAN AMERICAN (2013-2014)
22.8👇2006_-_2010 WHITE (2013-2014)
15.8☝2006_-_2010 HISPANIC (2013-2014)
——————————————————————
MICHIGAN – Estimated New Breast Cancer Cases:
——————————————————————
8,140☝2013 (State with 8th most)
7,710👇2012 (State with 8th most)
7,890☝2011 (State with 8th most)
7,340☝2010 (State with 8th most)
6,480☝2009 (State with 8th most)
6,120👇2008 (State with 9th most)
7,210👇2005 (State with 9th most)
7,270👇2004 (State with 9th most)
7,500☝2003 (State with 8th most)
7,300☝2002 (State with 8th most)
——————————————————————
Are these Dr. David H. Gorski’s “success stories” ?
——————————————————————
MICHIGAN – Estimated Breast Cancer Deaths:
——————————————————————
1,360☝2013 (State with 8th most)
1,350☝2012 (State with 8th most)
1,320 – 2011 (State with 9th most)
1,320👇2010 (State with 10th most)
1,350☝2009 (State with 9th most)
1,310 👇2008 (State with 9th most)
1,320 👇2007 (State with 9th most)
1,360 👇2006 (State with 9th most)
1,380☝2005 (State with 9th most)
1,350👇2004 (State with 9th most)
1,400 – 2003 (State tied with 8th most)
1,400☝2002 (State tied with 8th most)
——————————————————————
MICHIGAN – Cancer Incidence Rates
——————————————————————
120.3 – 2013 (State with 32nd most)
120.3👇2012 (State with 30th most)
122.2👇2011 (State with 24th most)
124.2👇2010 (State with 17th most)
127.0👇2009 (State with 11th most)
128.8👇2008 (State with 13th most)
129.4👇2007 (State tied with 18th most)
132.4👇2006 (State with 14th most)
133.5☝2005 (State with 13th most)
132.0☝1996_-_2000 (State with 14th most) 2004
129.8☝1995_-_1999 (State with 23rd most)(31st State’s) 2003
109.9👇1994_-_1998 Michigan – Cancer Incidence Rates (2002)
132.0☝1996_-_2000 (State with 14th most) (2004)
129.8☝1995_-_1999 (State with 23rd most) (2003)
109.9☝1994_-_1998 (State with 20th most) (2002)
——————————————————————
MICHIGAN – Cancer Death Rates:
——————————————————————
24.0👇2013 (State tied with 11th most)
24.4👇2012 (State tied with 13th most)
24.5👇2011 (State tied with 16th most)
25.1👇2010 (State tied with 12th most)
25.3👇2009 (State tied with 17th most)
25.8👇2008 (State tied with 18th most)
26.6👇2007 (State tied with 14th most)
27. 5 – 2006 (State tied with 12th most)
27.5👇2005 (State tied with 13th most)
28.4👇1996_-_2000 (State tied with 14th most) (2004)
29.5☝1995_-_1999 (State tied with 14th most) 2003
24.8☝1994_-_1998 (State with 14th most) 2002
——————————————————————
The problem, is that, when the Hippocratic Oath
was mentioned, Gorski may have opted for the Hypocrite Oath

Rather than address the BILLIONS of dollars in fines which Big Pharma racked up, and Pharma’s seeming dedication to getting members of the unwitting public, to take medications for symptoms which they were not approved for; and thus possibly experience adverse effects those drugs cause, Gorski chose to NOT comment about his goose that might lay the golden (parachute) nest egg

Instead, he tried the Tricky-Dicky trickle-down theory of Hackademic Mudicine (“Quackademic Medicine”); which did NOT work when Richard Milhous (“War on Cancer”) Nixon was told:

“There’s a cancer on the Presidency”

What Gorski seems hilariously oblivious to, is that his opprobrium; to turn a phrase, applies to him:
——————————————————————
(.3:16)
——————————————————————
When he mentions:

“ineffective and potentially harmful medical practices that were not, that are not supported by evidence”

he may as well be saying, in regards to surgery, chemotherapy, and radiation:

“ineffective and potentially harmful medical practices that were, that are supported by evidence“

(the evidence that they do NOT work for everyone)
——————————————————————
(.3:42)
——————————————————————
To use his own words, he seems:

“confused, at best”
——————————————————————
(.4:45)
——————————————————————
He also displays:

“an animosity toward reason”
——————————————————————
(.4:49)
——————————————————————
“Nothing’s changed within 30 years

If anything, it’s worse”
——————————————————————
(.6:45)
——————————————————————
He states:

“Alternative = unproved”

There goes “Alternative Rock,” or the “alternative” to an attempted Gorski joke: “happiness is a warm gun”

I’m somewhat surprised that Gorski has yet to classify antineoplastons as “Homeopathy: Ultra-diluted chemotherapy”
——————————————————————
(28:15)
——————————————————————
But he does rant that rival Cleveland Clinic where he had his residency, has been infiltrated by the Q.M.
——————————————————————
(39:10)
——————————————————————
And that his alma-mater, the University of Michigan has also queued in the “Quackademic” line
——————————————————————
(44:00)
——————————————————————
He bemoans the mighty wolverine:

“Again my alma-mater”

“I hang my head in shame”
——————————————————————
(44:10)
——————————————————————
And to add injury to insult, his “former employer,” UMDNJ (University of Medicine and Dentistry of New Jersey)-Robert Wood Johnson Medical School, New Brunswick, New Jersey, has also been bitten by the Quackademic Duck

I’m sure Gorski will be able to formulate a usual factoid #fail for his #failure to “cure” cancer, vis-a-vis “Orac”, the literary Hack, braying in the wilderness and awaiting his Red Badge of Courage

Maybe “too many people copulating” in Detroit, or too many Louisiana hurricane Katrina survivors added to the sandbox

Is Gorski a racist ?

That’s up to all the African American women in Detroit, Michigan, to decide

Maybe he’s just a really bad hypocrite

NOr, maybe he needs to spend less time on the “hypocuresy,” and more time on the “CURE”

Maybe the African American women of Detroit, Michigan, and the United States of America should ask Gorski:

What have you done for me lately ?
——————————————————————

——————————————————————
“And, make no mistake about it, antineoplastons (ANPs) are chemotherapy, no matter how much Burzynski tries to claim otherwise”
——————————————————————
NO, Gorski, the United States’ 5th Circuit Court of Appeals claimed that antineoplastons (ANPs) are:

“…an unapproved drug, not ordinary “chemotherapy”

no matter how much YOU try to claim otherwise

What are you ?

A Saul Green closet communist who does NOT believe what the United States’ Federal Courts rule ?

——————————————————————

——————————————————————
“Indeed, it was a blatant ploy, as Burzynski’s lawyer, Richard Jaffe, acknowledged, referring to one of his clinical trials as a “joke” and the others as a way to make sure there was a constant supply of new cancer patients to the Burzynski Clinic“
——————————————————————

——————————————————————
” … in 1997, his medical practice was expanded to include traditional cancer treatment options such as chemotherapy, gene targeted therapy, immunotherapy and hormonal therapy in response to FDA requirements that cancer patients utilize more traditional cancer treatment options in order to be eligible to participate in the Company’s Antineoplaston clinical trials“

“As a result of the expansion of Dr. Burzynski’s medical practice, the financial condition of the medical practice has improved Dr. Burzynski’s ability to fund the Company’s operations”
——————————————————————
GorskGeek, my citations, references, and / or links, beat your NON-citations, NON-references, and / or NON-links
======================================
AMERICAN CANCER SOCIETY:
CANCER FACTS & FIGURES (2002-2014)
======================================
2002_-_2003 – 1 of every 4 deaths
======================================
Deaths – United States of America
——————————————————————
2013 – almost 1,600 a day
2002-2012☝1,500+ a day
——————————————————————
Expected to Die – United States
——————————————————————
2013☝580,350_-_(3,160 more than 2012)
2012☝577,190_-_(5,240 more than 2011)
2011☝571,950_-_(2,460 more than 2010)
2010☝569,490_-_(7,150 more than 2009)
2009👇562,340_-_(3,310 less than 2008)
2008☝565,650_-_(6,000 more than 2007)
2007👇559,650_-_(5,180 less than 2006)
2006👇564,830_-_(5,450 less than 2005)
2005☝570,280_-_(6,580 more than 2004
2004☝563,700_-_(7,200 more than 2003)
2003☝556,500_-_(6,000 more than 2002)
2002☝555,500
——————————————————————
Estimated All Cancer Deaths (Women)
——————————————————————
2013👇273,430 (1,940 less than 2012)
2012☝275,370 (3,850 more than 2011)
2011☝271,520 (1,230 more than 2010)
2010☝270,290 (490 more than 2009)
2009👇269,800 (1,730 less than 2008)
2008☝271,530 (1,430 more than 2007)
2007👇270,100 (3,460 less than 2006)
2006👇273,560 (1,440 less than 2005)
2005☝275,000 (2,190 more than 2004)
2004☝272,810 (2,210 more than 2003)
2003☝270,600 (3,300 more than 2002)
2002_-_267,300
——————————————————————
Estimated cancer deaths – African Americans expected to die from cancer:
——————————————————————
2013👇64,645 – 22.6% (2013-2014)
2011☝65,540 (About) (2011-2012)
2009☝63,360 (About) (2009-2010)
2007☝62,780 (About) (2007-2008)
——————————————————————
Estimated Breast Cancer Deaths (Women)
——————————————————————
2013☝39,620 (14%) (110 more than 2012)
2012👇39,510 (14%) (10 less than 2011)
2011👇39,520 (15%) (320 less than 2010)
2010👇39,840 (15%) (330 less than 2009)
2009👇40,170 (15%) (310 less than 2008)
2008☝40,480 (15%) (20 more than 2007)
2007👇40,460 (15%) (2007-2008) (510 less than 2006)
2006☝40,970 (15%) (560 more than 2005)
2005☝40,410 (15%) (300 more than 2004)
2004☝40,110 (15%) (310 more than 2003)
2003☝39,800 (15%) (200 more than 2002)
2002 – 39,600 (15%)
——————————————————————
Estimated Deaths from Breast cancer expected to occur among African American women:
——————————————————————
6,080☝2013 – 19% (2013-2014)
6,040☝2011 – 19% (2011-2012)
6,020☝2009 – 19% (2009-2010)
5,830☝2007 – 19% (2007-2008)
5,640☝(2005-2006)
5,640 – 1969-2002 – 18.4% – 2005 (2005-2006)
======================================
New Cancer Cases Expected to be diagnosed – USA
——————————————————————
2013☝1,660,290 – (21,380 more than 2012)
2012☝1,638,910 – (42,240 more than 2011)
2011☝1,596,670 – (67,160 more than 2010)
2010☝1,529,560 – (49,810 more than 2009)
2009☝1,479,350 – (42,170 more than 2008)
2008👇1,437,180 – ( 7,740 less than 2007)
2007☝1,444,920 – (45,130 more than 2006)
2006☝1,399,790 – (26,880 more than 2005)
2005☝1,372,910 – ( 4,870 more than 2004)
2004☝1,368,030 – (33,930 more than 2003)
2003☝1,334,100 – (49,200 more than 2002)
2002☝1,284,900
——————————————————————
Estimated New Cancer All (Women)
——————————————————————
2013☝805,500 – (14,760 more than 2012)
2012☝790,740 – (16,370 more than 2011)
2011☝774,370 – (34,430 more than 2010)
2010☝739,940 – (26,720 more than 2009)
2009☝713,220 – (21,220 more than 2008)
2008☝692,000 – (13,940 more than 2007)
2007👇678,060 – (1,450 less than 2006)
2006☝679,510 – (16,640 more than 2005)
2005👇662,870 – (5,600 less than 2004)
2004☝668,470 – (9,670 more than 2003)
2003☝658,800 – (11,400 more than 2002)
2002_-_647,400
——————————————————————
Estimated New invasive Breast Cancer Cases: (Women)
——————————————————————
2013☝232,340 (29%) (5,470 more than 2012)
2012👇226,870 (29%) (11,610 less than 2011)
2011☝238,480 (30%) (31,390 more than 2010)
2010☝207,090 (28%) (14,720 more than 2009)
2009☝192,370 (27%) (9,910 more than 2008)
2008☝182,460 (26%) (3,980 more than 2007)
2007👇178,480 (26%) (2007-2008) (34,440 less than 2006)
2006☝212,920 (31%) (1,680 more than 2005)
2005👇211,240 (32%) (4,660 less than 2004)
2004☝215,900 (32%) (4,600 more than 2003)
2003☝211,300 (32%) (7,800 more than 2002)
2002_-_203,500 (31%)
——————————————————————
Estimated new cases – new cancer cases expected to be diagnosed among African Americans:
——————————————————————
2013☝176,620 (2013-2014)
2011☝168,900 (About) (2011-2012)
2009👇150,090 (About) (2009-2010)
2008☝182,460 (26%)
2007_-_152,900 (About) (2007-2008)
——————————————————————
Estimated new cases of in situ breast cancer expected to occur:
——————————————————————
64,640☝(2013) (1,340 more than 2012)
63,300☝(2012) (5,650 more than 2011)
57,650☝(2011) (3,640 more than 2010)
54,010👇(2010) (8,270 less than 2009)
62,280👇(2009) (5,490 less than 2008)
67,770☝(2008) (5,740 more than 2007-2008)
62,030☝(2007-2008) (50 more than 2006)
61,980☝(2006) (3,490 more than 2005-2006)
58,490👇(2005-2006) (900 less than 2004)
59,390☝(2004) (3,690 more than 2003)
55,700☝(2003) (1,400 more than 2002)
54,300☝(2002)
——————————————————————
Estimated New Cancer Cases – African Americans – Breast
——————————————————————
2013☝27,060 – 33% (2013-2014)
2011☝26,840 – 34% (2011-2012)
2009☝19,540 – 25% (2009-2010)
2007☝19,010 – 27% (2007-2008)
19,240 – 1979-2001 – 29.9% – 2005 (2005-2006)
——————————————————————
Estimated new cases of in situ breast cancer expected to occur = detection of below # of ductal carcinoma in situ (DCIS):
——————————————————————
54,944 (2013)
85% (2003-2012)
88% (2002)

1998-2002 accounted for about 85% of in situ breast cancers diagnosed (2005-2006)
1980-2001 – Incidence rates of DCIS increased more than sevenfold in all age groups, although greatest in women 50 and older (2005-2006)
——————————————————————
LEADING CAUSE OF DEATH
——————————————————————
2013 – breast cancer expected to be most commonly diagnosed cancer in women
——————————————————————
BREAST CANCER – 2nd
——————————————————————
2013 – Breast cancer 2nd most common cause of cancer death among African American women, surpassed only by lung cancer (2009-2012)
(2007)
——————————————————————
2003 – Breast cancer is 2nd among cancer deaths in women

2002-2003: 2nd leading cause of death

2002 – Breast cancer 2nd leading cause of death
————————————-
Breast cancer most common cancer among African American women

34% – (2011-2012)
25% – (2009-2010)
2007
——————————————————————
2011 – New Cases
(2011-2012)

New Cases: Breast cancer most commonly diagnosed cancer among African American women
——————————————————————
BREAST CANCER – AFRICAN AMERICAN WOMEN
——————————————————————
34% – African American women most common cancer (2011-2012)

African American Women Most common cancer (2005-2006)
——————————————————————
2005 – African American women – more likely to die from at any age
——————————————————————
ESTIMATED WOMEN BREAST CANCER DEATHS
——————————————————————
19% – number of cancer deaths breast cancer in women (2007-2012)
——————————————————————
since 1990 – Death rates from breast cancer steadily decreased in women (2009-2010)

since 1990 – death rate from breast cancer in women decreased (2007-2008)
——————————————————————
1.9% – 2000-2009 cancer mortality rate for women of all races combined declined annually (2012-2013)
——————————————————————
1990-2006 – death rate from breast cancer in women decreased (2005-2006)
——————————————————————
2.2% – 1990-2004 cancer mortality rate for women of all races combined decreased annually (2007-2008)

decline larger among younger age groups (2007-2008)
——————————————————————
2.3% – 1990-2002 rate decreased annually – percentage of decline larger among younger age groups (2005-2006)
——————————————————————
2.3% – 1990-2000 breast cancer death rates decreased annually (2005-2006)
——————————————————————
1992-1998 – mortality rates declined significantly

largest decreases in younger women, both white and black (2002)
——————————————————————
1.6% – 1975-1991 – Breast Cancer Death Rates Increased annually (2005-2006)
——————————————————————
0.4% – 1975-1990 – breast cancer death rates increased annually (2005-2006)
——————————————————————
0.4% – 1975-1990 death rate for all races combined increased annually (2005-2008)
——————————————————————
rate for women of all races combined decreased annually (2007-2008)

decline larger among younger age groups (2007-2008)
——————————————————————
BREAST CANCER – OLDER WOMEN
——————————————————————
Older women much more likely to get breast cancer than younger women
——————————————————————
% FEMALE BREAST CANCER DEATH RATES (age)
——————————————————————
97% – 1998-2002 – age 40 and older (2005-2008)
96% – 1996-2000 – age 40 and older (2005-2006)
——————————————————————
WOMEN YOUNGER than 50
——————————————————————
3.0% – under age of 50 – Mortality from breast cancer declined faster for women (annually from 2005-2009) regardless of race/ethnicity (2013)
——————————————————————
2.3% – 1990-2001 Breast Cancer Death Rates decrease

largest decrease in < 50 (2005-2006)
——————————————————————
3.7% – 1991-2000 under 50 breast cancer Death rates decreased (2005-2006)
——————————————————————
3.3% – 1990-2004 – death rates decreased per year among women younger than 50 (2005c-2008)
——————————————————————
2.3% – 1990-2002 Death rates from breast cancer declined average per year in all women combined, with larger decreases in younger (<50 years) women (2006)
——————————————————————
WOMEN 50 and older
——————————————————————
1.2% – 50 and older – decrease in breast cancer death rates smaller in African American than white women (2009-2010)
——————————————————————
2.0% – 50 and older – 1990-2004 – death rates decreased per year among women (2005-2008)
——————————————————————
WHITE WOMEN
——————————————————————
2.1% – 2000-2009 – breast cancer death rates declined per year in white women
——————————————————————
2.6% – 1992-2000 – breast cancer Death rates Whites (2005-2006)
——————————————————————
2.4% – 1990-2004 female breast cancer death rates declined per year in whites (2005-2008)
——————————————————————
early 1980’s – Breast Cancer Death Rates equal – African American / White (2005-2006)
——————————————————————
AFRICAN AMERICAN WOMEN – ALL CANCERS
——————————————————————
1.5% – since 1999 – Death rates among women (African Americans for all cancers combined) per year have been decreasing (2011-2012)
——————————————————————
AFRICAN AMERICAN WOMEN BREAST CANCER DEATHS
——————————————————————
black women more likely to die of breast cancer than white women (2012-2013)
——————————————————————
2005-2006 African American women more likely to die from breast cancer at every age
——————————————————————
41% – 2005-2009 African American women had higher death rate than white women despite lower incidence rate

39% – 2003-2007 – African American women had higher death rate than white women, despite lower incidence rate (2011-2012)

difference accounts for more than one-third (37%) of overall cancer mortality disparity between African American and white women (2011-2012)

37% – 2001-2005 – African American women had higher death rate than white women (2009-2010)

higher breast cancer mortality rate among African American women compared to white women occurs despite lower incidence rate (2009-2010)

difference accounts for more than one-third (37%) of overall cancer mortality disparity between African American and white women (2009-2010)

higher breast cancer mortality rate among African American women compared to white women occurs despite lower incidence rate (2007)

notable, striking divergence in long-term breast cancer mortality rates trends between African American and white women (2005-2008)

36% – by 2004 – death rates higher in African Americans than white women (2007-2008)
37% – by 2002 – death rates higher in African American women than white women (2005-2006)
36% – 2000-2003 – death rates higher in African American women than white women (2007)

difference accounts for one-third of excess cancer mortality experienced by African American women compared to white women (2007)

32% – 2000 – Breast Cancer Death rate higher in African American women even though had lower incidence rates (2005-2006)
——————————————————————
AFRICAN AMERICAN WOMEN – 50 and older
——————————————————————
1.2% – 50 and older – 1992-2012 – per year – women (2011-2012)

2.0% – 50 and older – Breast Cancer Death Rates – per year (2009-2010)
——————————————————————
1.2% – 50 and older – decrease in breast cancer death rates smaller in African American than white women (2009-2010)

1.1% – 50 and older – 1991-2007 – African American women Breast cancer death rates declined annually (2007)

2.0% – 50 and older – 1990-2000 – breast cancer Death rates decreased (2005-2006)
——————————————————————
1990 – 50 and older – Breast Cancer Death Rates Increase predominantly due to
——————————————————————
AFRICAN AMERICAN WOMEN – under 50
——————————————————————
2.0% – 1992-2012 – decrease larger in women under 50 – declined thereafter per year (2011-2012)

1.9% – 1992-2009 – decrease larger in women under 50 – declined thereafter per year (2009-2010)

resulted in growing disparity

3.3% per year – larger decreases in women younger than 50 – Breast Cancer Death Rates (2009-2010)
——————————————————————
1.9% – 1991_-_2007 – decrease larger in women under 50 – African American women Breast cancer death rates declined annually per year
——————————————————————
AFRICAN AMERICAN WOMEN
——————————————————————
2000-2009 – death among females, rate of decline similar

As result, overall racial disparity narrowed
——————————————————————
2000-2009 death rate declined faster among African Americans females rate of decline than whites

1.5% – 2000-2009 African Americans females rate of decline per year (2013-2014)

1.4% – 2000-2009 whites rate of decline per year (2013-2014 )
——————————————————————
1.4% – 2000-2009 – breast cancer death rates declined more slowly per year in African American women
——————————————————————
1990-2002
African American women benefited less than white women from advances (2005-2008)
——————————————————————
1.1% – breast cancer death rates African Americans (2005-2006)
——————————————————————
1.6% – 1995-2004 – female breast cancer death rates declined per year in African Americans (2007-2008)

1.0% – 1990-2002 female breast cancer death rates declined per year – African Americans (2005-2006)
——————————————————————
early 1990s – Death rates among African Americans for all cancers combined have been decreasing (2011-2012)
——————————————————————
breast cancer death rates have declined more slowly in African American women compared to white women, which has resulted in growing disparity (2011-2012)
——————————————————————
gap much smaller among women
racial difference in overall cancer death rates due largely to cancers of breast and colorectum in women

racial disparity has widened for breast cancer in women (2011-2012)
——————————————————————
early 1980s – disparity in breast cancer death rates between African American and white women began in (2007-2008)
——————————————————————
early 1980s – breast cancer death rates for white and African American women approximately equal (2007)
——————————————————————
30% – early 1980’s-2000 – disparity between African American and white Deaths (2005-2006)
——————————————————————
early 1980s – disparity in breast cancer death rates between African American and white women appeared (2005-2006)
——————————————————————
early 1980s – breast cancer death rates for white and African American women

similar (2011-2014)

equal (2009-2010)

early 1980’s – Breast Cancer Death Rates equal – African American / White (2005-2006)
——————————————————————
1.5% – 1975-1992 – Breast cancer death rates among African American women increased annually (2009-2012)

1.6% – 1975-1991 – African American women Breast cancer death rates increased annually (2007)
——————————————————————
1975-2007 – death rates for all cancers combined continued to be substantially higher among African Americans than whites (2011-2012)
——————————————————————
AFRICAN AMERICAN WOMEN BREAST CANCER DEATH RATE RATIOS per 100,000 women
——————————————————————
35.4 – African American – 1997-2001 – Breast Cancer Death Rate Ratios per 100,000 (2005-2006)

26.4 – White – 1997-2001 – Breast Cancer Death Rate Ratios per 100,000 (2005-2006)

1.3 – African American / White Ratio – 1997-2001 – Breast Cancer Death Rate Ratios per 100,000 (2005-2006)
——————————————————————
HISPANIC / LATINA WOMEN
——————————————————————
2.4% – 1995-2004 female breast cancer death rates declined per year in Hispanics / Latinas (2007-2008)
1.8% – 1990-2002 female breast cancer death rates declined per year in Hispanics / Latinas (2005-2006)
1.4% – breast cancer Death rates Hispanics (2005-2006)

1990-2002
women of other racial and ethnic groups benefited less than white women from advances (2005-2008)
——————————————————————
ASIAN AMERICAN / PACIFIC ISLANDER WOMEN
——————————————————————
1995-2004 female breast cancer death rates remained unchanged among Asian Americans/Pacific Islanders (2007-2008)

1.1% – breast cancer Death rates Asian and Pacific Islanders (2005-2006)

1.0% – 1990-2002 female breast cancer death rates declined per year – Asian Americans / Pacific Islanders (2005-2006)
——————————————————————
1990-2002
women of other racial and ethnic groups benefited less than white women from advances (2005-2008)
——————————————————————
AMERICAN INDIAN / ALASKA NATIVE WOMEN
——————————————————————
1995-2004 female breast cancer death rates remained unchanged among American Indians / Alaska Natives (2007-2008)

1990-2002 female breast cancer death rates did not decline in American Indian / Alaska Natives (2005-2006)
——————————————————————
1990-2002
women of other racial and ethnic groups benefited less than white women from advances (2005-2008)
——————————————————————
breast cancer Death rates American Indian and Alaska Native – constant (2005-2006)
——————————————————————
DEATHS – 2007-2008
——————————————————————
40,460 – Deaths – All ages (2007-2008)
23,510 – Deaths – 65 and older (2007-2008)
16,950 – Deaths – Younger than 65 (2007-2008)
31,320 – Deaths – 55 and older (2007-2008)
9,140 – Deaths – Younger than 55 (2007-2008)
37,630 – Deaths – 45 and older (2007-2008)
2,830 – Deaths – Younger than 45 (2007-2008)
——————————————————————
MORTALITY (DEATH) RATES
——————————————————————
31.0 – Black – Mortality – 1992-1998 – Mortality Rates* by Site, Race, and Ethnicity (2002)

24.3 – White – Mortality – 1992-1998 – Mortality Rates* by Site, Race, and Ethnicity (2002)

14.8 – Hispanic – Mortality – 1992-1998 – Mortality Rates* by Site, Race, and Ethnicity (2002)

12.4 – American Indian / Alaskan Native – Mortality – 1992-1998 – Mortality Rates* by Site, Race, and Ethnicity (2002)

11.0 – Asian / Pacific Islander – Mortality – 1992-1998 – Mortality Rates* by Site, Race, and Ethnicity (2002)
——————————————————————
WHITE WOMEN – MORE LIKELY TO DEVELOP BREAST CANCER
——————————————————————
Combining all age groups, white (non-Hispanic) women more likely to develop breast cancer than black women
——————————————————————
PROBABILITY of DEVELOPING BREAST CANCER in NEXT 10 YEARS (Age)
——————————————————————
20
——————————————————————
20 – 0.05% – 1 in 2,152 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
20 – 0.05% – 1 in 1,985 – 2000-2002 probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
20 – 0.05% – 1 in: 1,837 – probability of developing breast cancer in next 10 years (2007-2008)
——————————————————————
30
——————————————————————
30 – 0.44% – 1 in: 229 (2000-2002) probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
30 – 0.43% – 1 in: 234 – probability of developing breast cancer in next 10 years (2007-2008)
——————————————————————
30 – 0.40% – 1 in 251 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
40
——————————————————————
40 – 1.46% – 1 in: 68 (2000-2002) probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
40 – 1.45% – 1 in 69 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
40 – 1.43% – 1 in: 70 – probability of developing breast cancer in next 10 years (2007-2008)
——————————————————————
50
——————————————————————
50 – 2.78% – 1 in 36 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
50 – 2.73% – 1 in: 37 (2000-2002) probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
50 – 2.51% – 1 in: 40 – probability of developing breast cancer in next 10 years (2007-2008)
——————————————————————
60
——————————————————————
60 – 3.82% – 1 in: 26 (2000-2002) probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
60 – 3.81% – 1 in 26 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
60 – 3.51% – 1 in: 28 – probability of developing breast cancer in next 10 years (2007-2008)
——————————————————————
70
——————————————————————
70 – 4.31% – 1 in 23 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
70 – 4.14% – 1 in: 24 (2000-2002) probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
70 – 3.88% – 1 in: 26 – probability of developing breast cancer in next 10 years (2007-2008)
——————————————————————
LIFETIME RISK
——————————————————————
13.2% – 1 in 8 – 2005-2006 Currently, woman living in US has, or, lifetime risk of developing breast cancer
——————————————————————
13.22% – Lifetime risk – 1 in: 8 – 2000-2002 probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
12.28% – Lifetime risk – 1 in: 8 – probability of developing breast cancer in next 10 years (2007-2008)
——————————————————————
AFRICAN AMERICAN LIFE EXPECTANCY
——————————————————————
2007 – life expectancy lower for African Americans than whites among women

(76.5 vs. 80.6 years) (2011-2012)
——————————————————————
DEVELOPING INVASIVE BREAST CANCER
——————————————————————
1 in 8 – 2013 – chance of developing invasive breast cancer during lifetime
——————————————————————
1 in 8 – 12.3% – Currently, woman living in US has lifetime risk of developing breast cancer (2007-2008)
——————————————————————
about 1 in 11 – 1975
——————————————————————
1 in 11 – 1970s – lifetime risk of being diagnosed with breast cancer (2007-2008)
——————————————————————
result of rounding to nearest whole number, small decrease in lifetime risk (from 1 in 7.47 to 1 in 7.56) led to change in lifetime risk from 1 in 7 previously reported in Breast Cancer Facts & Figures 2003-2004 and Cancer Facts & Figures 2005 to current estimate of 1 in 8

Overall, lifetime risk of being diagnosed with breast cancer gradually increased over past 3 decades (2005-2006)
——————————————————————
INVASIVE BREAST CANCER – by age (2007-2008)
——————————————————————
178,480 – All ages
72,520 – 65 and older
105,960 – Younger than 65
124,300 – 55 and older
54,180 – Younger than 55
162,330 – 45 and older
16,150 – Younger than 45
——————————————————————
INVASIVE BREAST CANCER – by # (2007-2008)
——————————————————————
178,480 – All ages
162,330 – 45 and older
124,300 – 55 and older
105,960 – Younger than 65
72,520 – 65 and older
54,180 – Younger than 55
16,150 – Younger than 45
——————————————————————
INVASIVE BREAST CANCER
——————————————————————
0.3% – 1987-2002 – Incidence Trends: increased per year (2005-2006)
————————————-
—————————–
4% (almost) – 1980-1987 – increased (almost +4% a year) Incidence Trends (2005-2006)
——————————————————————
age 40-49
——————————————————————
Since 1987 – age 40-49 – incidence rates of invasive breast cancer have slightly declined (2005-2006)

3.5% – 40-49 (age) – 1980-1987 – incidence rates of invasive breast cancer increased among women per year – Incidence Trends: Invasive Breast Cancer (2005-2006)
——————————————————————
age 50 and older
——————————————————————
Since 1987 – 50 and older – incidence rates of invasive breast cancer have continued to increase among women, though at much slower rate (2005-2006)

4.2% – 50 and older – incidence rates of invasive breast cancer increased among women per year – Incidence Trends: Invasive Breast Cancer (2005-2006)
——————————————————————
Under 40
——————————————————————
Under 40 – remained essentially constant (2005-2006)

Since 1987 – younger than 40 – relatively little change in incidence rates of invasive breast cancer in women (2005-2006)
——————————————————————
Invasive Breast Cancer
——————————————————————
1975-2000 – Invasive Breast Cancer (2005-2006):

4% – 40 and older – increased 1980-1987 then stabilized (2005-2006)
——————————————————————
1992-2002 – overall incidence rates did not change significantly among whites, African Americans, and Hispanics / Latinas (2005-2006)
——————————————————————
1.3% – Hispanics – increased overall (2005-2006)
——————————————————————
0.9% – Whites – increased overall (2005-2006)
——————————————————————
African Americans – stabilized (2005-2006)
——————————————————————
Asian Americans / Pacific Islanders
——————————————————————
2.1% – 1992-2002 – Asian and Pacific Islanders – overall incidence rates increased overall (2005-2006)

1.5% – 1992-2002 – Asian Americans / Pacific Islanders – overall incidence rates increased per year (2005-2006)

trends in invasive female breast cancer incidence rates (2005-2006)
——————————————————————
American Indian / Alaska Natives
——————————————————————
3.7% – American Indian / Alaska Native – decreased overall (2005-2006)

3.5% – 1992-2002 – American Indian / Alaska Natives – overall incidence rates decreased per year (2005-2006)

trends in invasive female breast cancer incidence rates (2005-2006)
——————————————————————
essentially constant – Incidence Trends
——————————————————————
1973-1980 – essentially constant – Incidence Trends (2005-2006)
——————————————————————
African Americans more likely to be diagnosed at later stage of disease when treatment choices are more limited and less effective (2013-2014)
——————————————————————
MEDIAN AGE of DIAGNOSIS
——————————————————————
62 – median age of diagnosis for -white women
——————————————————————
57 – median age of diagnosis for African American women
——————————————————————
DIAGNOSIS at LOCAL STAGE
——————————————————————
61% – breast cancers diagnosed among white women at local stage (2011-2012)
——————————————————————
51% (Only about half) – of breast cancers diagnosed among African American women are local stage (2011-2014)
——————————————————————
MEDIAN AGE AT TIME OF BREAST CANCER DIAGNOSIS
——————————————————————
61 – 2000_-_2004 median age at time of breast cancer diagnosis (2007-2008)
61 – 1998_-_2002 median age at time of breast cancer diagnosis
——————————————————————
61 – means 50% of women who developed breast cancer were 61 or younger (2007-2008)
50% of women who developed breast cancer were age 61 or younger 1998_-_2002
——————————————————————
61 – 50% were older than 61 when diagnosed (2007-2008)

50% were older than age 61 when diagnosed 1998_-_2002
——————————————————————
2005_-_2009 % / age DIAGNOSED with BREAST CANCER
——————————————————————
61 – median age for breast cancer diagnosis

0.0% – under age 20
1.8% – between 20-34
9.9% – between 35-44
22.5% – between 45-54
24.8% – between 55-64
20.2% – between 65-74
15.1% – between 75-84
5.7% – 85+
——————————————————————
2005_-_2009 % / age DIAGNOSED with BREAST CANCER by % (SEER, 2012)
——————————————————————
24.8% – between 55-64
22.5% – between 45-54
20.2% – between 65-74
15.1% – between 75-84
9.9% – between 35-44
5.7% – 85+
1.8% – between 20-34
0.0% – under age 20
——————————————————————
IN SITU BREAST CANCER – by age (2007-2008)
——————————————————————
62,030 – All ages
21,510 – 65 and older
40,520 – Younger than 65
37,110 – 55 and older
24,920 – Younger than 55
54,390 – 45 and older
7,640 – Younger than 45
——————————————————————
IN SITU BREAST CANCER – by # (2007-2008)
——————————————————————
62,030 – All ages
54,390 – 45 and older
40,520 – Younger than 65
37,110 – 55 and older
24,920 – Younger than 55
21,510 – 65 and older
7,640 – Younger than 45
——————————————————————
NEW CASES – IN SITU BREAST CANCER
——————————————————————
increase observed in all age groups, although greatest in women 50 and older (2007-2008)
——————————————————————
Since 2000 – incidence rates of in situ breast cancer leveled off among women 50 and older (2007-2008)
——————————————————————
Since 2000 – incidence rates of in situ breast cancer have continued to increase in younger women (2007-2008)
——————————————————————
80% – 2000-2004 – Most in situ breast cancers are ductal carcinoma (DCIS), which accounted for about 80% of in situ breast cancers diagnosed (2007-2008)
——————————————————————
2000-2004 – Lobular carcinoma in situ (LCIS) less common than DCIS, accounting for about 10% of female in situ breast cancers diagnosed (2007-2008)

Similar to DCIS, overall incidence rate of LCIS increased more rapidly than incidence of invasive breast cancer (2007-2008)

increase limited to women older than age 40 and largely to postmenopausal women (2007-2008)
——————————————————————
1998-2002 accounting for female in situ breast cancers diagnosed (2005-2006):

12% – Lobular carcinoma in situ (LCIS) less common than DCIS

Similar to DCIS, overall incidence rate of LCIS increased more rapidly than incidence of invasive breast cancer

increase limited to women older than 40 and largely to postmenopausal women
——————————————————————
1980s and 1990s – Incidence rates of in situ breast cancer increased rapidly (2007-2008)
——————————————————————
New cancer cases in women expected to be newly diagnosed among African Americans:
——————————————————————
2013 – 82,080 (About)
——————————————————————
19% – breast cancer in women (2007-2008)
——————————————————————
2002 – Breast cancer ranks 2nd among cancer deaths in women
——————————————————————
2002-2003: 2nd leading cause of death
——————————————————————
African American women expected to die from cancer:
——————————————————————
African Americans have the highest death rate and shortest survival of any racial and ethnic group in the US for most cancers
(2007-2014)
African Americans have the highest mortality rate of any racial and ethnic group in the US for most cancers
(2005-2006)
——————————————————————
higher death rate in African
American women compared to white women occurs despite lower cancer incidence rate (2013-2014)
——————————————————————
African American women have higher death rates overall and for breast and several other cancer sites (2013-2014)
——————————————————————
15% – 2009 – death rate for all cancers combined continued to be higher in African American women than in white women (2013-2014)
——————————————————————
racial difference in overall cancer death rates is due largely to cancers of the breast and colorectum in women (2013-2014)
——————————————————————
overall racial disparity in cancer death rates decreasing (2013-2014)
——————————————————————
16% – 2007 – death rate for all cancers combined higher in African American women than white women (2011-2012)
——————————————————————
37% – by 2002 – death rates higher in African Americans than white women (2005-2006)
——————————————————————
since early 1990s – death rates among African Americans for all cancers combined have been decreasing (2013-2014)
——————————————————————
30% – early 1980’s–2000 – Deaths disparity between African American and white (2005–2006)
——————————————————————
1975-2009 – Despite declines, death rates for all cancers combined continued to be higher among African Americans than whites (2013-2014)
——————————————————————
1992-2014 – Breast cancer death rates among African American women declined
——————————————————————
1.4% per year – 2000-2009 – breast cancer death rates declined more slowly in African American women
——————————————————————
2.1% per year – 2000-2009 – breast cancer death rates declined white women
——————————————————————
early 1980s – breast cancer death rates for white and African American women similar
——————————————————————
1975-1992 – Breast cancer death rates among African American women increased
resulted in growing disparity
——————————————————————
through 1998 – breast cancer incidence rates among young white women continued to increase more slowly (2002)
——————————————————————
1980s – 4.5% per year increase (2002)
——————————————————————
As result, overall racial disparity narrowed (2013-2014)
——————————————————————
1992-1998 – mortality rates declined significantly – largest decreases in younger women, both white and black (2002)
——————————————————————
1992-1998 – Incidence and Mortality Rates* by Site, Race, and Ethnicity (2002)
——————————————————————
Incidence
——————————————————————
115.5 – White
101.5 – Black
78.1 – Asian / Pacific Islander
50.5 – American Indian / Alaskan Native
68.5 – Hispanic
——————————————————————
Mortality
——————————————————————
31.0 – Black
24.3 – White
14.8 – Hispanic
12.4 – American Indian / Alaskan Native
11.0 – Asian / Pacific Islander
——————————————————————
Cancer Facts & Figures for African Americans 2005-2006
——————————————————————
1995-2000 (2001) – Diagnosed
Female breast (2005-2006):
——————————————————————
Localized
——————————————————————
64% – White (2005-2006)
53% – African American (2005-2006)
——————————————————————
Regional
——————————————————————
35% – African American (2005-2006)
28% – White (2005-2006)
——————————————————————
Distant
——————————————————————
9% – African American (2005-2006)
5% – White (2005-2006)
——————————————————————
Unstaged
——————————————————————
3% – African American (2005-2006)
2% – White (2005-2006)
——————————————————————
2005-2006 – Cancer Incidence Rates Ratios per 100,000 (1975-2001)
——————————————————————
1997-2001 – Breast (2005-2006)
143.2 – White (2005-2006)
118.6 – African American (2005-2006)
0.8 – African American / White Ratio (2005-2006)
——————————————————————
2005-2006 – Cancer Death Rate Ratios per 100,000
——————————————————————
1997-2001 – Breast (2005-2006)
35.4 – African American (2005-2006)
26.4 – White (2005-2006)
1.3 – African American / White Ratio (2005-2006)
——————————————————————
Most common cancer among African American Women (2005-2006)
——————————————————————
17% lower incidence rate in African American than White (2005-2006)
——————————————————————
under 40 – higher incidence rate in African American than White (2005-2006)
——————————————————————
25 years incidence:
——————————————————————
1999-2001 – leveling off (2005-2006)
1986-1999 – less rapid increase (2005-2006)
1978-1986 – rapid increase (2005-2006)
1975-1978 – stable (2005-2006)
——————————————————————
Breast Cancer Death Rates Increased (2005-2006):
——————————————————————
1975-1991 – + 1.6% – annually (2005-2006)
——————————————————————
1991 – decided annually: particularly in women younger than 50 (2005-2006)
——————————————————————
Breast Cancer Death Rates (2005-2006):
——————————————————————
early 1980’s – equal – African American / White (2005-2006)
——————————————————————
2000 – 32% – higher African American (2005-2006)
——————————————————————
Death rate higher in African American even though had lower incidence rates (2005-2006)
——————————————————————
Rate per 100,000
——————————————————————
White
African American
Asian or Pacific Islander
Hispanic
American Indian or Alaska Native
——————————————————————
1996-2000 – Incidences:

140.8 – White
121.7 – African American
97.2 – Asian or Pacific Islander
89.8 – Hispanic
58 – American Indian or Alaska Native
——————————————————————
1996-2000 – Deaths

35.9 – African American
27.2 – White
17.9 – Hispanic
14.9 – American Indian or Alaska Native
12.5 – Asian or Pacific Islander
——————————————————————
Estimated New In Situ Cases:
——————————————————————
2003_-_100 – < 30
2005 – 1,600 – Under 40
2003 – 2,100 – 30-39
2005 – 56,890 – 40 and older
2005 – 13,760 – Under 50
2003 -12,600 – 40-49
2005 – 44,730 – 50 and older
2005 – 37,040 – Under 65
2003 – 15,700 – 50-59
2005 – 21,450 – 65 and older
2003 – 11,500 – 60-69
2003 – 10,100 – 70-79
2003 – 3,500 – 80 +
2005 – 58,490 – All ages
TOTAL
2003 – 55,700
——————————————————————
2003_-_100 – 0.2%
2003 – 2,100 – 3.8%
2003 – 12,600 – 22.6%
2003 – 15,700 – 28.2%
2003 – 11,500 – 20.6%
2003 – 10,100 – 18.1%
2003 – 3,500 – 16.3
TOTAL
2003 – 100.0%
——————————————————————
Estimated New Invasive Cases:
——————————————————————
2003 – 1,000 – < 30
2005 – 9,510 – Under 40
2003 – 10,500 – 30-39
2005_-_201,730 – 40 and older
2005 – 45,780 – Under 50
2003 – 35,500 – 40-49
2005_-_165,460 – 50 and older
2005_-_123,070 – Under 65
2003 – 48,700 – 50-59
2005 – 88,170 – 65 and older
2003 – 43,100 – 60-69
2003 – 45,600 – 70-79
2003 – 27,000 – 80 +
2005_-_211,240 – All ages
TOTAL
2003 – 55,700 –
——————————————————————
2003 – 1,000 – 0.5%
2003 – 10,500 – 5.0%
2003 – 35,500 – 16.8%
2003 – 48,700 – 23.0%
2003 – 43,100 – 20.4%
2003 – 45,600 – 21.6%
2003 – 27,000 – 12.8%
TOTAL
2003 – 100.00%
——————————————————————
Deaths:
——————————————————————
2003_-_100 – < 30
2005 – 1,110 – Under 40
2003 – 1,300 – 30-39
2005 – 39,300 – 40 and older
2005 – 5,590 – Under 50
2003 – 4,300 – 40-49
2005 – 34,820 – 50 and older
2005 – 17,470 – Under 65
2003 – 7,000 – 50-59
2005 – 22,940 – 65 and older
2003 – 7,400 – 60-69
2003 – 9,500 – 70-79
2003 – 10,100 – 80 +
2005 – 40,410 – All ages
TOTAL
2003 – 39,800
——————————————————————
2003_-_100 – 0.3%
2003 – 1,300 – 3.3%
2003 – 4,300 – 10.8%
2003 – 7,000 – 17.6 %
2003 – 7,400 – 18.6%
2003 – 9,500 – 23.9%
2003 – 10,100 – 25.4%
TOTAL
2003 – 100.0
——————————————————————
1990 – Increase since predominantly due to women 50 and older
——————————————————————
1998-2002 accounting for female in situ breast cancers diagnosed (2005-2006):
——————————————————————
12% – Lobular carcinoma in situ (LCIS) less common than DCIS

Similar to DCIS, overall incidence rate of LCIS increased more rapidly than incidence of invasive breast cancer

increase limited to women older than 40 and largely to postmenopausal women
——————————————————————
1990-2001 (2005-2006):
——————————————————————
2.3% – decrease
largest decrease in < 50
——————————————————————
1998-2002 women aged 40 and older (2005-2006):
——————————————————————
95% – new cases
97% – breast cancer deaths
——————————————————————
1996-2000 Women 40 and older (2005-2006):
——————————————————————
94% – New Cases
96% – Deaths
——————————————————————
0.3% per year – Incidence rates declined slightly among white females (2013-2014)
——————————————————————
1996-2002 (2005-2006):
——————————————————————
20-24 – 1.3 per 100,000 lowest incidence rate – 1998-2002 (2005-2006)

20-24 – 1.4 per 100,000 lowest incidence rate – 1996-2000 (2005-2006)
——————————————————————
75-79 – 496.6 per 100,000 highest incidence rate – 1998-2002 (2005-2006)

75-79 – 499.0 per 100,000 highest incidence rate – 1996-2000 (2005-2006)
——————————————————————
2005-2006
•
White women higher incidence of breast cancer than African American women after 35

African American women slightly higher incidence rate before 35

African American women more likely to die from breast cancer at every age
——————————————————————
2005

White – higher incidence rate than African American women after 40

African American – slightly higher incidence rate before 40

African American women – more likely to die from at any age
——————————————————————
2005-2006 incidence and death rates from breast cancer lower among women of other racial and ethnic groups than white and African American women
——————————————————————
2000-2009 – stable among African American females (2013-2014)
——————————————————————
1975-1980 essentially constant (2005-2006)
1980-1987 + almost 4% per year (2005-2006)
1987-2002 + 0.3% per year (2005-2006)
•
Incidence Trends
Invasive Breast Cancer (2005-2006):

1973-1980 – essentially constant (2005-2006)
1980-1987 – + almost 4% year (2005-2006)
1987-2000 – 0.4% year (2005-2006)
——————————————————————
1980-1987 incidence rates of invasive breast cancer increased among women (2005-2006):
——————————————————————
40-49 (3.5% per year) (2005-2006)
50 and older (4.2% per year) (2005-2006)
Since 1987
50 and older – rates have continued to increase among women , though at much slower rate (2005-2006)

40-49 -rates have slightly declined (2005-2006)

younger than 40 – relatively little change in incidence rates of invasive breast cancer in women (2005-2006)

1975-2000 – Invasive Breast Cancer (2005-2006):

4% – 40 and older increased 1980 – 1987 then stabilized (2005-2006)

Under 40 – remained essentially constant (2005-2006)
——————————————————————
2005-2006 trends in invasive female breast cancer incidence rates:
——————————————————————
1992-2002
(1.5% per year) – overall incidence rates increased in Asian Americans / Pacific Islanders (2005-2006)

(3.5% per year) – decreased in American Indian/Alaska Natives (2005-2006)

did not change significantly among whites, African Americans, and Hispanics/Latinas (2005-2006)

1992-2000 – Invasive (2005-2006):

2.1% – Asian and Pacific Islanders – increased overall (2005-2006)
1.3% – Hispanics – increased overall (2005-2006)
0.9% – Whites – increased overall (2005-2006)
3.7% – American Indian and Alaska Native – decreased overall (2005-2006)
——————————————————————
African Americans – stabilized (2005-2006)
——————————————————————
since 1990 – death rate from breast cancer in women decreased (2005-2006)
——————————————————————
1975-1990
0.4% – death rate for all races combined increased annually (2005-2006)
•
1990-2002
2.3% – rate decreased annually
percentage of decline larger among younger age groups (2005-2006)

1990-2002
3.3% – death rates decreased per year among women younger than 50 (2005-2006)

2.0% – per year among women 50 and older (2005-2006)

African American women and women of other racial and ethnic groups have benefited less than white women from advances (2005-2006)

1990-2002 female breast cancer death rates declined (2005-2006):

2.4% – per year – whites (2005-2006)
1.8% – per year – Hispanics/Latinas (2005-2006)
1.0% – per year – African Americans and Asian Americans/Pacific Islanders (2005-2006)

did not decline in American Indian/ Alaska Natives (2005-2006)
——————————————————————
life expectancy lower for African Americans than whites among women (77.2 vs. 80.9 years) (2013-2014)
——————————————————————
As result, overall racial disparity narrowed (2013-2014)
——————————————————————
striking divergence in long-term mortality trends between African American and white females (2005-2006)
——————————————————————
early 1980s – disparity in breast cancer death rates between African American and white women appeared (2005-2006)
——————————————————————
1975-1990 – Death (2005-2006):
0.4% – increased annually (2005-2006)
——————————————————————
1990-2000
2.3% – decreased annually (2005-2006)
——————————————————————
1991-2000
3.7% – under 50 decreased (2005-2006)
——————————————————————
1990-2000
2.0% – 50 and older decreased (2005-2006)
——————————————————————
1992-2000 – Death (2005-2006):
——————————————————————
2.6% – Whites (2005-2006)
1.4% – Hispanics (2005-2006)
1.1% – African Americans (2005-2006)
1.1% – Asian and Pacific Islanders (2005-2006)
American Indian and Alaska Native – constant (2005-2006)
——————————————————————
Probability of developing Breast Cancer in next 10 years:
——————————————————————
Age
——————————————————————
20 – 0.05% – 1 in 2,152 (2005-2006)
20 – 0.05% – 1 in 1,985 – 2000-2002 (2005-2006)†
——————————————————————
30 – 0.40% – 1 in 251 (2005-2006)
30 – 0.44% – 1 in: 229 – 2000-2002 (2005-2006)†
——————————————————————
40 – 1.45% – 1 in 69 (2005-2006)
40 – 1.46% – 1 in: 68 – 2000-2002 (2005-2006)†
——————————————————————
50 – 2.78% – 1 in 36 (2005-2006)
50 – 2.73% – 1 in: 37 – 2000-2002 (2005-2006)†
——————————————————————
60 – 3.81% – 1 in 26 (2005-2006)
60 – 3.82% – 1 in: 26 – 2000-2002 (2005-2006)†
——————————————————————
70 – 4.31% – 1 in 23 (2005-2006)
70 – 4.14% – 1 in: 24 – 2000-2002 (2005-2006)†
——————————————————————
Lifetime Probability (%) of Developing or Dying from Invasive Cancers by Race and Sex
——————————————————————
Developing

12.73 (1 in 8) – White (%) 2007-2009 (2013-2014)

10.87 (1 in 9) – African American (%) 2007-2009 (2013-2014)

Dying

3.25 (1 in 31) – African American (%) 2007-2009 (2013-2014)

2.73 (1 in 37) – White (%) 2007-2009 (2013-2014)

2005-2006 Currently, woman living in US has 13.2%, or 1 in 8, lifetime risk of developing breast cancer (2013-2014)

result of rounding to nearest whole number, small decrease in lifetime risk (from 1 in 7.47 to 1 in 7.56) led to change in lifetime risk from 1 in 7 previously reported in Breast Cancer Facts & Figures 2003-2004 and Cancer Facts & Figures 2005 to current estimate of 1 in 8

2005-2006: Overall, lifetime risk of being diagnosed with breast cancer gradually increased over past 3 decades (2013-2014)
——————————————————————
13.22% – Lifetime risk – 1 in: 8
Comparison of Cancer Incidence Rates between African Americans and Whites
——————————————————————
123.2 – White Rate* 2005-2009 (2013-2014)
121.7 – White Rate* 2003-2007 (2011-2012)
130.6 – White Rate* 2001-2005 +
——————————————————————
118.1 – African American Rate* 2005-2009 (2013-2014)
114.7 – African American Rate* 2003-2007 (2011-2012)
117.6 – African American Rate* 2001-2005 +
——————————————————————
-5.1 – Difference† 2005-2009 (2013-2014)
-7.0 – Absolute Difference† 2003-2007 (2011-2012)
-13.1 – Absolute Difference† 2001-2005 +
——————————————————————
0.96 – Rate Ratio‡ 2005-2009 (2013-2014)
0.94 – Rate Ratio‡ 2003-2007 (2011-2012)
0.90 – Rate Ratio‡ 2001-2005 +

*Rates per 100,000 age adjusted to 2000 US standard population

†Difference is rate in African Americans minus rate in whites

†Absolute difference is rate in African Americans minus rate in whites

‡Rate ratio is unrounded rate in African Americans divided by unrounded rate in whites

‡Rate ratio is rate in African Americans divided by rate in whites based on 2 decimal places

+ Source: Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries 2000-2005, Division of Cancer Control and Population Sciences, National Cancer Institute, 2008
——————————————————————
Comparison of Cancer Death Rates between African Americans and Whites
——————————————————————
31.6 – African American Rate* 2005-2009
32.4 – African American Rate* 2003-2007 (2011-2012)
33.5 – African American Rate* 2001-2005 +
——————————————————————
22.4 – White Rate* 2005-2009
23.4 – White Rate* 2003-2007 (2011-2012)
24.4 – White Rate* 2001-2005 +
——————————————————————
9.2 – Difference† 2005-2009
9.0 – Absolute Difference† 2003-2007 (2011-2012)
9.1 – Absolute Difference† 2001-2005 +
——————————————————————
1.41 – Rate Ratio‡ 2005-2009
1.39 – Rate Ratio‡ 2003-2007 (2011-2012)
1.37 – Rate Ratio‡ 2001-2005 +

*Rates per 100,000 and age adjusted to 2000 US standard population

†Difference is rate in African Americans minus rate in whites

†Absolute difference is rate in African Americans minus rate in whites

‡Rate ratio is unrounded rate in African Americans divided by unrounded rate in whites

‡Rate ratio is rate in African Americans divided by rate in whites based on 2 decimal places

+ Source: Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries 2000-2005, Division of Cancer Control and Population Sciences, National Cancer Institute, 2008
——————————————————————
Stage Distribution for Selected Cancers in African Americans and Whites

Stage Distribution African Americans and Whites
——————————————————————
Localized
——————————————————————
61% – White 2002-2008
61% – White 1999-2006
62% – White 1996-2004 +
——————————————————————
51% – African American 2002-2008
51% – African American 1999-2006
51% – African American 1996-2004 +
——————————————————————
Regional

38% – African American 2002-2008
39% – African American 1999-2006
37% – African American 1996-2004 +
——————————————————————
32% – White 2002-2008
32% – White 1999-2006
31% – White 1996-2004 +
——————————————————————
Distant
——————————————————————
8% – African American 2002-2008
8% – African American 1999-2006
10% – African American 1996-2004 +
——————————————————————
5% – White 2002-2008
5% – White 1999-2006
6% – White 1996-2004 +
——————————————————————
Unstaged
——————————————————————
3% – African American 2002-2008
3% – African American 1999-2006
3% – African American 1996-2004 +
——————————————————————
2% – White 2002-2008
2% – White 1999-2006
2% – White 1996-2004 +
——————————————————————
+ Source:
Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries, 1973-2005, Division of Cancer Control and Population Sciences, National Cancer Institute, 2008
——————————————————————
Probability of Developing Invasive Cancers Over Selected Age Intervals among African Americans by Sex +

Probability of Developing Invasive Cancers:
——————————————————————
Birth to 39 (%):
——————————————————————
0.53 (1 in 189) 2003-2005 * +
0.44 (1 in 229) 1998–2000 (2004)
0.44 (1 in 228) 1997–1999 (2003)
0.44 (1 in 229) 1996–1997 (2002)
——————————————————————
40 to 59(%):
——————————————————————
3.56 (1 in 28) – 40 to 59(%) 2003-2005 * +
4.14 (1 in 24) 1998–2000 (2004)
4.17 (1 in 24) 1997–1999 (2003)
4.17 (1 in 24) 1996–1997 (2002)

2.96 (1 in 34) – 60 to 69 (%) 2003-2005 * +
——————————————————————
60 to 79 (%):
——————————————————————
7.53 (1 in 13) 1998–2000 (2004)
7.14 (1 in 14) 1997–1999 (2003)
7.14 (1 in 14) 1996–1997 (2002)

5.44 (1 in 18) – 70 and Older (%) 2003-2005 * +
——————————————————————
Birth to Death (%)
——————————————————————
9.91 (1 in 10) – Birth to Death (%) 2003-2005 * +
13.36 (1 in 7) 1998–2000 (2004)
13.3 (1 in 8) 1997–1999 (2003)
12.5 (1 in 8) 1996–1997 (2002)

*For people free of cancer at beginning of age interval

+ Source:
DevCan:
Probability of Developing or Dying of Cancer Software, Version 6.3.0. Statistical Research and Applications Branch, National Cancer Institute, 2008
——————————————————————
2005-2006 Currently, woman living in US has 13.2%, or 1 in 8, lifetime risk of developing breast cancer (2013-2014)

result of rounding to nearest whole number, small decrease in lifetime risk (from 1 in 7.47 to 1 in 7.56) led to change in lifetime risk from 1 in 7 previously reported in Breast Cancer Facts & Figures 2003-2004 and Cancer Facts & Figures 2005 to current estimate of 1 in 8
——————————————————————
2005-2006: Overall, lifetime risk of being diagnosed with breast cancer gradually increased over past 3 decades (2013-2014)
——————————————————————
5-YEAR SURVIVAL RATE – ALL
——————————————————————
Survival after diagnosis of breast cancer continues to decline after 5 years (2009-2010)

Survival after diagnosis of breast cancer continues to decline beyond 5 years (2006)
——————————————————————
5-YEAR RELATIVE SURVIVAL LOWER
——————————————————————
5-year relative survival lower among women with more advanced stage at diagnosis (2007-2008)

5-year relative survival lower among women with more advanced stage of disease at diagnosis (2005-2006)
——————————————————————
2005-2006 African American women with breast cancer less likely than white women to survive 5 years:
——————————————————————
90% – white
76% – African American
——————————————————————
Likely to survive 5 years (2005-2006):
——————————————————————
88% – White
74% – African American
——————————————————————
5-YEAR SURVIVAL RATE – ALL STAGES – COMBINED
——————————————————————
89% – survival rate at 5 years for all stages combined (2009-2010)
——————————————————————
88% – all stages combined – 5 year
——————————————————————
77% – all stages combined – 10 year
——————————————————————
5-YEAR RELATIVE SURVIVAL RATE for ALL CANCERS COMBINED
——————————————————————
63% – 2004
62% – 2002-2003
——————————————————————
5-year Relative Survival Rates* for Cancers by Race and Stage

Five-year Relative Survival Rates* for Cancers by Race and Stage at Diagnosis

Five-Year Relative Survival Rates

5-year Relative Survival Rates (1995-2000 (2001) diagnosed) SEER 1975–2001 (2004)
——————————————————————
Localized
——————————————————————
99% – White 2002-2008 (2013-2014)
61% – White 1999-2006 (2011-2012)
99% – White 1996-2004 +
98% – White 1995–2000 (2005–2006)
——————————————————————
93% – African American 2002-2008 (2013-2014)
51% – African American 1999-2006 (2011-2012)
93% – African American 1996-2004 +
91% – African American 1995–2000 (2005–2006)
——————————————————————
Regional
——————————————————————
85% – White 2002-2008 (2013-2014)
32% – White 1999-2006 (2011-2012)
85% – White 1996-2004 +
82% – White 1995–2000 (2005–2006)
——————————————————————
73% – African American 2002-2008 (2013-2014)
39% – African American 1999-2006 (2011-2012)
72% – African American 1996-2004 +
68% – African American 1995–2000 (2005–2006)
——————————————————————
Distant
——————————————————————
25% – White 2002-2008 (2013-2014)
5% – White 1999-2006 (2011-2012)
29% – White 1996-2004 +
27% – White 1995–2000 (2005–2006)
——————————————————————
15% – African American 2002-2008 (2013-2014)
8% – African American 1999-2006 (2011-2012)
17% – African American 1996-2004 +
15% – African American 1995–2000 (2005–2006)
——————————————————————
All Stages
——————————————————————
90% – White 2002-2008 (2013-2014)
2% – White 1999-2006 (2011-2012)
90% – White 1996-2004 +
56% – White 1995–2000
(2005–2006)
——————————————————————
78% – African American 2002-2008 (2013-2014)
3% – African American 1999-2006 (2011-2012)
77% – African American 1996-2004 +
50% – African American 1995–2000 (2005-2006)
——————————————————————
*Survival rates based on patients diagnosed 2002-2008 followed through 2009

*Survival rates based on patients diagnosed 1999-2006 followed through 2007

Survival rates based on patients diagnosed 1996 – 2004 followed through 2005 +

Local:
invasive cancer confined entirely to organ of origin

Regional:

malignant cancer either

1) extended beyond limits of organ of origin directly into surrounding organs or tissues

2) involves regional lymph nodes by way of lymphatic system

3) both regional extension and involvement of regional lymph nodes

Distant:

malignant cancer spread to parts of body remote from primary tumor either by direct extension or by discontinuous metastasis to distant organs, tissues, or via lymphatic system to distant lymph nodes

+ Source:
Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries, 1973-2005, Division of Cancer Control and Population Sciences, National Cancer Institute, 2008
——————————————————————
Considering all races, 5-year relative survival:

98% – localized disease
81% – regional disease
26% – distant-stage disease

Larger tumor size at diagnosis associated with decreased survival
among women of all races with regional disease, 5-year relative survival:

92% – tumors less than or equal to 2.0 cm
77% – tumors 2.1-5.0 cm
65% – tumors greater than 5.0 cm
——————————————————————
OVERALL 5-YEAR CANCER SURVIVAL RATE (2005-2006)
——————————————————————
55% – 1995-2000 (2005-2006)
27% – 1960-1963 (2005-2006)
——————————————————————
5-YEAR RELATIVE SURVIVAL RATES
——————————————————————
89% – 5 year relative survival rates for women diagnosed with breast cancer after diagnosis (2007-2008)
88% – 5 year relative survival rates for women diagnosed with breast cancer after diagnosis (2005-2006)
87% – 5 year Breast Cancer Survival Rates after Diagnosis (2005-2006)
——————————————————————
age 75 + – 5 year relative survival rate among women diagnosed with breast cancer
——————————————————————
88% – 75 and older (2005-2006)
86% – 75 and over (2005-2006)
——————————————————————
age 65 + – 5 year relative survival rate among women diagnosed with breast cancer
——————————————————————
89% – 65-74 (2005-2006)
88% – 65 and over (2005-2006)
——————————————————————
5-year relative survival rate among women diagnosed with breast cancer
——————————————————————
88% – 55-64 (2005-2006)
89% – 40-74 (2005-2006)
87% – 45-54 (2005-2006)
83% – 45 (less than) (2005-2006)
——————————————————————
40 and older – 5-year relative survival rate
——————————————————————
89% – 40 and older – 5-year relative survival rate slightly lower among women diagnosed with breast cancer (2007-2008)
——————————————————————
younger than 40 – 5-year relative survival rate
——————————————————————
82% – before 40 – slightly lower among women diagnosed with breast cancer (2007-2008)
——————————————————————
82% – younger than 40 – slightly lower among women diagnosed with breast cancer before age 40 – may be due to tumors in age group being more aggressive (2005-2006)
——————————————————————
All – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
86% – 1992-1997 (2002) – 1974-1997
78% – 1983-1985 (2002) – 1974-1997
75% – 1974-1976 (2002) – 1974-1997
——————————————————————
WHITE WOMEN
——————————————————————
69% – white women (2013-2014)
——————————————————————
62% – white women (2007)
——————————————————————
90% – 1999-2006 white women (2011-2012)
——————————————————————
90% – 1996-2004 white women – 5-year relative survival rate for breast cancer diagnosed (2009-2010)
——————————————————————
90% – white women with breast cancer to survive 5 years (2007-2008)
——————————————————————
5-year survival greater among white women (2007)
——————————————————————
90% – 2002-2008 – overall 5-year relative survival rate for breast cancer diagnosed among white women
——————————————————————
88% – White women – Likely to survive 5 years (2005-2006)
——————————————————————
81% – White women – 5 year survivors: relative 5 year survival rate (2005-2006)
——————————————————————
62% – 1996-2004 – white women – 5-year relative survival rate for breast cancer diagnosed (2009-2010)
——————————————————————
90% – 1996-2002 – whites (2007) – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
——————————————————————
90% – 1996-2002 – White – 5-Year Relative Survival – Breast 2007 (2007-2008) +
——————————————————————
89% – 1995-2000 – White – 5-year Relative Survival (1995-2000 (2001) Diagnosis) SEER 1975-2001 (2004) (2005-2006)
——————————————————————
87% – 1992-1997 – White – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
——————————————————————
79% – 1983-1985 – White – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
——————————————————————
75% – 1974-1976 – White – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
——————————————————————
AFRICAN AMERICAN WOMEN
——————————————————————
78% – black women still living 5 years after getting disease (SEER, 2012)
——————————————————————
78% – 1999-2006 – 5-year relative survival rate for breast cancer diagnosed among African American women Survival and Stage at Distribution (2011-2012)
——————————————————————
76% – African American – 5 year survivors relative 5 year survival rate (2005-2006)
——————————————————————
74% – African American – Likely to survive 5 years (2005-2006)
——————————————————————
60% – African Americans – continue to have lower 5-year survival than whites overall and for each stage of diagnosis for most cancer sites (2013-2014)

African Americans continue to be less likely than whites to survive 5 years at each stage of diagnosis for most cancer sites (2009-2010)

Within each stage, 5-year survival also lower among African American women (2009-2010)

78% – 2002-2008 – overall 5-year relative survival rate for breast cancer diagnosed among African American women

77% – African American women with breast cancer less likely than white women to survive 5 years (2007-2008)
76% – African American women with breast cancer less likely than white women to survive 5 years 2005-2006

60% – 2002-2008 – overall 5-year relative survival rate among African Americans improved (2013-2014)

59% – 1999-2006 – African Americans continue to be less likely than whites to survive 5 years at each stage of diagnosis for most cancer sites (2011-2012)

58% – 1996-2004 – overall 5-year relative survival rate among African Americans improved (2009-2010)

77% – 1996-2002 – 5-Year Relative Survival – Breast – African American 2007 (2007-2008) +
77% – 1996-2002 – African American women (2007) – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)

72% – 1992-1997 – Black – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)

63% – 1983-1985 – Black – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)

63% – 1974-1976 – Black – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)

27% – 1960-1963 – overall 5-year relative survival rate among African Americans improved (2009-2014)
——————————————————————
1996-2002 – 5-Year Relative Survival – Breast 2007 – (Based on cancer patients diagnosed 1996-2002 followed through 2003) (2007-2008) +

(Source: Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries, 1975-2003, Division of Cancer Control and Population Sciences, National Cancer Institute, 2006) (2007-2008)
——————————————————————
relative survival rates for women diagnosed with breast cancer (2005-2006):
•
88% – 5 years after diagnosis (2005-2006)
80% – 10 years (2005-2006)
71% – 15 years (2005-2006)
63% – 20 years (2005-2006)
•
Breast Cancer Survival Rates after Diagnosis:
•
87% – 5 years (2005-2006)
77% – 10 years (2005-2006)
63% – 15 years (2005-2006)
52% – 20 years (2005-2006)
——————————————————————
2005-2006 – 5-year relative survival rate slightly lower among women diagnosed with breast cancer before age 40
•
may be due to tumors in age group being more aggressive and less responsive to hormonal therapy:
•
82% – younger than 40 (2005-2006)
89% – 40 – 74 (2005-2006)
88% – 75 and older (2005-2006)
•
5 year relative survival rate (2005-2006):
•
83% – < 45
87% – 45 – 54
88% – 55 – 64
89% – 65 – 74
88% – 65 and over
86% – 75 and over
——————————————————————
5 year survivors
relative 5 year survival rate (2005-2006):
•
81% – White
76% – African American
——————————————————————
10 year survivors after diagnosis
relative 5 year survival rate (2005-2006):
——————————————————————
87% – White
85% – African American
——————————————————————
LOCALIZED CANCER INCIDENCE RATES RATIOS per 100,000 (1975-2001) – 1995-2000 (2001) – Diagnosed Female breast (2005-2006): Localized – Of all breast cancers diagnosed 2005-2006
——————————————————————
143.2 – White
118.6 – African American

0.8 – African American / White Ratio
——————————————————————
2005-2006
1995-2000 – 5-year Relative Survival (1995-2000 (2001) Diagnosis) SEER 1975-2001 (2004)
89% – White (2005-2006)
75% – African American (2005-2006)
——————————————————————
2005-2006
1995-2000 – 5-year Relative Survival Rates (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004)
Female breast
——————————————————————
Localized
——————————————————————
98% – White (2005-2006)
91% – African American (2005-2006)
——————————————————————
Regional
——————————————————————
82% – White (2005-2006)
68% – African American (2005-2006)
——————————————————————
Distant
——————————————————————
27% – White (2005-2006)
15% – African American (2005-2006)
——————————————————————
Unstaged
——————————————————————
56% – White (2005-2006)
50% – African American (2005-2006)
——————————————————————
LOCALIZED 5-YEAR RELATIVE SURVIVAL RATES (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004) Female breast (2005-2006)
——————————————————————
98% – 1995-2000 – White
91% – 1995-2000 – African American
——————————————————————
LOCALIZED
——————————————————————
98% – 2010 – 5-year relative survival for localized breast cancer (malignant cancer that has not spread to lymph nodes or other locations outside breast) has increased (2009-2010)

98% – localized disease: 5-year relative survival – Considering all races (2007-2008)

98% – 2006 – 5-year relative survival for localized breast cancer (cancer not spread to lymph nodes or other locations outside breast) increased

98% – localized disease – 2005-2006 5-year relative survival lower among women with more advanced stage of disease at diagnosis: Considering all races

98% – 2005 – 5 year relative survival for localized

97% – 2004 – 5-year relative survival for localized breast cancer (cancer not spread to lymph nodes or other locations outside breast) increased

96% – 2002 – 5-year relative survival for localized breast cancer (cancer not spread to lymph nodes or other locations outside breast) increased

99% – 1996-2002 White – localized (2007-2008) *

94% – 1996-2002 African American – localized (2007-2008) *

80% – 1950s – 5-year relative survival for localized breast cancer (malignant cancer that has not spread to lymph nodes or other locations outside breast) has increased (2009-2010)

80% – 1950s – 5-year relative survival for localized breast cancer (cancer not spread to lymph nodes or other locations outside breast) increased (2006)

72% – 1940s – 5-year relative survival rate for localized breast cancer (cancer not spread to lymph nodes or other locations outside breast) increased (2002)
——————————————————————
5-year relative survival rate for breast cancer diagnosed at local stage
——————————————————————
77% – 1996-2004 – African American women – 5-year relative survival rate for breast cancer diagnosed at local stage (2009-2010)
——————————————————————
LOCALIZED
——————————————————————
62% – 1996-2002 White – Localized – Stage Distribution – Female breast (2007-2008)

64% – White – Localized (2005–2006)

64% – 1995-2000 (2001) – White: Diagnosed Female breast (2005-2006): Localized – Of all breast cancers diagnosed

5% – 1995-2000 (2001) – White: Diagnosed Female breast (2005-2006): Localized – Of all breast cancers diagnosed

52% – 1996-2002 African American – Localized – Stage Distribution – Female breast (2007-2008)

53% – African American – Localized (2005–2006)

53% – 1995-2000 (2001) – African American: Diagnosed Female breast (2005-2006): Localized – Of all breast cancers diagnosed
——————————————————————
REGIONAL 5-YEAR RELATIVE SURVIVAL RATES (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004) Female breast (2005-2006)
——————————————————————
82% – 1995-2000 – White
68% – 1995-2000 – African American
——————————————————————
REGIONALLY
——————————————————————
84% – cancer spread regionally, current 5-year survival (2009-2010)

84% – regional disease – 5-year relative survival: Considering all races (2007-2008)

81% – regional disease – 5-year relative survival lower among women with more advanced stage of disease at diagnosis: Considering all races 2005-2006

85% – 1996-2002 White – Regional (2007-2008) *

80% – cancer spread regionally

78% – 2002 – 5-year relative survival rate: breast cancer spread regionally

72% – 1996-2002 African American – Regional (2007-2008) *
——————————————————————
36% – 1996-2002 African American – Regional: Stage Distribution – Female breast (2007-2008)

30% – 1996-2002 White – Regional: Stage Distribution – Female breast (2007-2008)

35% – African American – Regional (2005–2006)

35% – 1995-2000 (2001) – African American: Diagnosed
Female breast (2005-2006): Regional – Of all breast cancers diagnosed

28% – White – Regional (2005–2006)
——————————————————————
REGIONAL TUMORS
——————————————————————
94% – Larger tumor size at diagnosis also associated with decreased survival among women of all races with regional disease, 5-year relative survival for tumors less than or equal (2007-2008)

92% – tumors less than or equal to 2.0 cm – Larger tumor size at diagnosis associated with decreased survival among women of all races with regional disease, 5-year relative survival

77% – tumors 2.1-5.0 cm – Larger tumor size at diagnosis associated with decreased survival among women of all races with regional disease, 5-year relative survival

65% – tumors greater than 5.0 cm – Larger tumor size at diagnosis associated with decreased survival among women of all races with regional disease, 5-year relative survival
——————————————————————
DISTANT
——————————————————————
27% – women with distant spread (metastases) 5-year survival (2009-2010)

27% – 1995-2000 – White – Distant 5-year Relative Survival Rates (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004) Female breast (2005-2006)

27% – distant-stage disease: 5-year relative survival, Considering all races (2007-2008)

26% – distant metastasis

26% – distant-stage disease – 2005-2006 5-year relative survival lower among women with more advanced stage of disease at diagnosis: Considering all races

28% – 1996-2002 White – Distant (2007-2008) *

21% – 2002 – 5-year relative survival rate: breast cancer distant metastasis

16% – 1996-2002 African American – Distant (2007-2008) *

15% – 1995-2000 – African American – Distant 5-year Relative Survival Rates (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004) Female breast (2005-2006)

28% – 1995-2000 (2001) – White: Distant – Diagnosed Female breast (2005-2006): Of all breast cancers diagnosed
——————————————————————
9% – 1996-2002 African American – Distant – Stage Distribution African Americans – Female breast (2007-2008)

9% – African American – Distant (2005–2006)

9% – 1995-2000 (2001) – African American: Diagnosed
Female breast (2005-2006): Localized – Of all breast cancers diagnosed

6% – 1996-2002 White – Distant – Stage Distribution Whites – Female breast (2007-2008)

5% – White – Distant (2005–2006)
——————————————————————
UNSTAGED
——————————————————————
56% – 1996-2002 – Unstaged – White (2007-2008) *

56% – 1995-2000 – White – Unstaged 5-year Relative Survival Rates (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004) Female breast (2005-2006)

50% – 1995-2000 – Unstaged – African American – 5-year Relative Survival Rates (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004) Female breast (2005-2006)

45% – 1996-2002 – Unstaged – African American (2007-2008) *
——————————————————————
3% – 1996-2002 African American – Unstaged – Stage Distribution Whites – Female breast (2007-2008)

3% – African American – Unstaged (2005–2006)

3% – 1995-2000 (2001) – African American: Unstaged – Of all breast cancers diagnosed – Diagnosed
Female breast (2005-2006)

2% – 1996-2002 White – Unstaged – Stage Distribution Whites – Female breast (2007-2008)

2% – White – Unstaged (2005–2006)

2% – 1995-2000 (2001) – White: Diagnosed Female breast (2005-2006): Unstaged – Of all breast cancers diagnosed
——————————————————————
ALL – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
90% – 1999-2006 (2011) – 1975-2006
87% – 1992-1999 (2004)
87% – 1992-1999 (2004) – 1974-1999
86% – 1974-1998 (2003)
86% – 1992-1998 (2003) – 1974-1998
86% – 1992-1997 (2002) – 1974-1997
79% – 1984-1986 (2011) – 1975-2006
78% – 1983-1985 (2004)
78% – 1983-1985 (2004) – 1974-1999
78% – 1983-1985 (2002) – 1974-1997
75% – 1975-1977 (2011) – 1975-2006
78% – 1974-1998 (2003)
75% – 1974-1976 (2004)
75% – 1974-1976 (2004) – 1974-1999
75% – 1974-1976 (2002) – 1974-1997
——————————————————————
WHITE WOMEN – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
91% – 1999-2006 (2011) – 1975-2006
90% – 1996-2002 (2007)
88% – 1992-1999 (2004)
88% – 1992-1999 (2004) – 1974-1999
88% – 1992-1998 (2003) – 1974-1998
88% – 1974-1998 (2003)
87% – 1992-1997 (2002) – 1974-1997
81% – 1984-1986 (2011) – 1975-2006
79% – 1983-1985 (2004)
79% – 1983-1985 (2004) – 1974-1999
79% – 1983-1985 (2002) – 1974-1997
76% – 1975-1977 (2011) – 1975-2006
75% – 1974-1976 (2004)
75% – 1974-1976 (2004) – 1974-1999
75% – 1974-1976 (2002) – 1974-1997
——————————————————————
AFRICAN AMERICAN WOMEN – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
78% – 1999-2006 (2011) – 1975-2006
77% – 1996-2002 (2007)
74% – 1992-1999 (2004)
74% – 1992-1999 (2004) – 1974-1999
73% – 1992-1998 (2003) – 1974-1998
73% – 1974-1998 (2003)
72% – 1992-1997 (2002) – 1974-1997
65% – 1984-1986 (2011) – 1975-2006
64% – 1983-1985 (2004)
64% – 1983-1985 (2004) – 1974-1999
63% – 1983-1985 (2002) – 1974-1997
63% – 1974-1998 (2003)
63% – 1974-1976 (2004)
63% – 1974-1976 (2004) – 1974-1999
63% – 1974-1976 (2002) – 1974-1997
62% – 1975-1977 (2011) – 1975-2006
——————————————————————
COMBINED – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
91% – 1999-2006 – White Women – 1975-2006 (2011)
90% – 1999-2006 – All – 1975-2006 (2011)
90% – 1996-2002 – White Women (2007)
87% – 1992-1997 – White Women – 1974-1997 (2002)
86% – 1992-1997 – All – 1974-1997 (2002)
81% – 1984-1986 – White Women – 1975-2006 (2011)
79% – 1984-1986 – All – 1975-2006 (2011)
79% – 1983-1985 – White Women – 1974-1997 (2002)
78% – 1999-2006 – African American Women – 1975-2006 (2011)
78% – 1983-1985 – All – 1974-1997 (2002)
77% – 1996-2002 – African American Women (2007)
76% – 1975-1977 – White Women – 1975-2006 (2011)
75% – 1975-1977 – All – 1975-2006 (2011)
75% – 1974-1976 – All – 1974-1997 (2002)
75% – 1974-1976 – White Women – 1974-1997 (2002)
72% – 1992-1997 – African American Women – 1974-1997 (2002)
65% – 1984-1986 – African American Women – 1975-2006 (2011)
63% – 1983-1985 – African American Women – 1974-1997 (2002)
63% – 1974-1976 – African American Women – 1974-1997 (2002)
62% – 1975-1977 – African American Women – 1975-2006 (2011)
——————————————————————
COMBINED by YEAR – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
91% – 1999-2006 – White Women – 1975-2006 (2011)
90% – 1999-2006 – All – 1975-2006 (2011)
78% – 1999-2006 – African American Women – 1975-2006 (2011)
——————————————————————
90% – 1996-2002 – White Women (2007)
77% – 1996-2002 – African American Women (2007)
——————————————————————
87% – 1992-1997 – White Women (2002)
86% – 1992-1997 – All (2002)
72% – 1992-1997 – African American Women (2002)
——————————————————————
81% – 1984-1986 – White Women – 1975-2006 (2011)
79% – 1984-1986 – All – 1975-2006 (2011)
65% – 1984-1986 – African American Women – 1975-2006 (2011)
——————————————————————
79% – 1983-1985 – White Women (2002)
78% – 1983-1985 – All (2002)
63% – 1983-1985 – African American Women (2002)
——————————————————————
76% – 1975-1977 – White Women – 1975-2006 (2011)
75% – 1975-1977 – All – 1975-2006 (2011)
62% – 1975-1977 – African American Women – 1975-2006 (2011)
——————————————————————
75% – 1974-1976 – All (2002)
75% – 1974-1976 – White Women (2002)
63% – 1974-1976 – African American Women (2002)
——————————————————————
Stages (%) – 5-Year Relative Survival Rates by Stage at Diagnosis
——————————————————————
97.0% – 1992-1999 – Local (2004)
97% – 1992-1998 – Local (2003)
96% – 1992-1997 – Local (2002)
——————————————————————
88% – 2006 – All Stages (2006)
86.6% – 1992-1999 – All Stages (2004)
86% – 1992-1998 – All Stages (2003)
86% – 1992-1997 – All Stages (2002)
——————————————————————
81% – Regional (2006)
78.7% – 1992-1999 – Regional (2004)
78% – 1992-1998 – Regional (2003)
78% – 1992-1997 – Regional (2002)
——————————————————————
26% – 2006 – distant metastases (2006)
23.3% – 1992-1999 – Distant (2004)
23% – 1992-1998 – Distant (2003)
21% – 1992-1997 – Distant metastases (2002)
——————————————————————
*
——————————————————————
1996-2002 – 5-Year Relative Survival Rates (5-year relative survival rate among cancer patients diagnosed 1996-2002 followed through 2003) *

Female breast – (Source: Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries, 1973-2003, Division of Cancer Control and Population Sciences, National Cancer Institute, 2006) (2007-2008)

Local:

invasive cancer confined entirely to organ

Regional:

malignant cancer

1) extended beyond limits of organ of origin directly into surrounding organs or tissues

2) involves regional lymph nodes by way of lymphatic system

3) has both regional extension and involvement of regional lymph nodes

Distant:

cancer spread to parts of body remote from primary tumor either by direct extension or by discontinuous metastasis to distant organs, tissues, or via lymphatic system to distant lymph nodes

Source:

Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries, 1975-2003, Division of Cancer Control and Population Sciences, National Cancer Institute, 2006 (2007-2008)
——————————————————————
5-YEAR SURVIVAL – INVASIVE BREAST CANCER
——————————————————————
90% – 2002-2008 – women diagnosed with invasive breast cancer still living 5 years after getting disease (SEER, 2012)
——————————————————————
10-YEAR SURVIVAL RATES
——————————————————————
Caution should be used when interpreting 10-year survival rates since they represent detection and treatment circumstances 5-17 years ago and may underestimate expected survival based on current conditions (2009-2010)

Caution should be used when interpreting long-term survival rates since they reflect experience of women treated using past therapies and do not reflect recent trends in early detection or advances in treatment (2007-2008)
——————————————————————
87% – White – 10 year survivors after diagnosis relative 5 year survival rate (2005-2006)
——————————————————————
85% – African American – 10 year survivors after diagnosis relative 5 year survival rate (2005-2006)
——————————————————————
81% – 10 year – relative survival rates for women diagnosed with breast cancer (2007-2008)
——————————————————————
80% – 10 year – survival rate for all stages combined (2009-2010)
——————————————————————
80% – 10 years after diagnosis – relative survival rates for women diagnosed with breast cancer (2005-2006)
——————————————————————
77% – 10 year – Breast Cancer Survival Rates after Diagnosis (2005-2006)
——————————————————————
15-YEAR SURVIVAL RATE
——————————————————————
73% – 15 year – relative survival rates for women diagnosed with breast cancer (2007-2008)
——————————————————————
71% – 15 years after diagnosis – relative survival rates for women diagnosed with breast cancer (2005-2006)
——————————————————————
63% – 15 years – Breast Cancer Survival Rates after Diagnosis (2005-2006)
——————————————————————
20-YEAR SURVIVAL RATE
——————————————————————
63% – 20 years after diagnosis – relative survival rates for women diagnosed with breast cancer (2005-2006)
——————————————————————
52% – 20 years – Breast Cancer Survival Rates after Diagnosis (2005-2006)
======================================
Breast Cancer
American Cancer Society
Cancer Facts & Figures (2002-2014)
======================================
REFERENCES:
======================================
[A] – .7/30/2013, Tuesday – Karmanos Cancer Center’s Dr. David Gorski appointed program co-director of Michigan Breast Oncology Quality Initiative:
——————————————————————
http://www.karmanos.org/News/Default.aspx?sid=1&nid=359
======================================
[B] – .7/30/2013 – Dr. Gorski named co-director of Michigan Breast Oncology Quality Initiative:
——————————————————————
http://prognosis.med.wayne.edu/article/dr-gorski-named-codirector-of-michigan-breast-oncology-quality-initiative
======================================
[C] – 07/30/2013 – Dr. Gorski named co-director of Michigan Breast Oncology Quality Initiative : ——————————————————————
http://www.wsupgdocs.org/news-and-media/WayneStateContentPage.aspx?nd=1293&news=515
======================================
[D] – 2/1/2011 – Barbara Ann Karmanos Cancer Center Names Dr. David Gorski Leader of Breast Multidisciplinary Team:
/PRNewswire-USNewswire/ — The Barbara Ann Karmanos Cancer Center has named David Gorski, M.D., Ph.D., leader of the Breast Multidisciplinary Team (MDT), effective Tuesday, Feb. 1
——————————————————————
http://m.prnewswire.com/news-releases/barbara-ann-karmanos-cancer-center-names-dr-david-gorski-leader-of-breast-multidisciplinary-team-115018114.html
======================================
[E] – 11/2/2011, Wednesday – Make the Right Move:
——————————————————————
http://www.karmanos.org/News/breast-cancer-specialists
======================================
[F]
——————————————————————
http://cancerbiologyprogram.med.wayne.edu/faculty/gorski.php
======================================
[G] – Research Interest:
——————————————————————
http://www.wsusurgery.com/research-team-dr-gorski/
======================================
[H]
——————————————————————
http://wsusurgery.com/facultyc3/david-gorski/
——————————————————————
http://www.wsusurgery.com/facultyc3/david-gorski/
======================================
[I]
——————————————————————
http://wsusurgery.com/research-team-dr-gorski/
——————————————————————
http://www.wsusurgery.com/research-team-dr-gorski/
======================================
[J]
——————————————————————
http://karmanos.org/Physicians/Details.aspx?sid=1&physician=70
——————————————————————
http://www.karmanos.org/Physicians/Details.aspx?sid=1&physician=70
======================================
[K]
——————————————————————
http://sciencebasedmedicine.org/editorial-staff/
——————————————————————
http://www.sciencebasedmedicine.org/editorial-staff/
======================================
[L]
——————————————————————
http://www.scienceinmedicine.org/fellows/GorskiD.html
——————————————————————
http://scienceinmedicine.org/fellows/GorskiD.html
======================================
[M]
——————————————————————
http://sciencebasedmedicine.org/editorial-staff/david-h-gorski-md-phd-managing-editor/
——————————————————————
http://www.sciencebasedmedicine.org/editorial-staff/david-h-gorski-md-phd-managing-editor/
======================================
[N]
——————————————————————
http://scienceblogs.com/insolence
======================================
[O]
——————————————————————
http://ncas.org/2013/02/mar-9-david-h-gorski-quackademic.html?m=1
——————————————————————
http://www.ncas.org/2013/02/mar-9-david-h-gorski-quackademic.html?m=1
======================================
[P]
——————————————————————
http://whybiotech.com/?p=3808
——————————————————————
http://www.whybiotech.com/?p=3808
======================================
[Q]
——————————————————————
http://en.wikipedia.org/wiki/David_Gorski
======================================
[R] – Breast Cancer Research – Dr. Gorski:
——————————————————————
http://www.wsusurgery.com/breast-cancer-research-dr-gorski/
======================================
[S] – Selected Publications:
——————————————————————
http://www.wsusurgery.com/selected-publications-dr-gorski/
======================================
[T] – Lab Photos:
——————————————————————
http://www.wsusurgery.com/lab-photos-dr-gorski/
======================================
[U]
——————————————————————
https://www.doximity.com/pub/david-gorski-md
======================================
[V] – Detroit, Michigan population
——————————————————————
http://www.worldpopulationstatistics.com/detroit-population-2013/
======================================
[W]
——————————————————————
http://quickfacts.census.gov/qfd/states/26/2622000.html
======================================
[X]
——————————————————————
http://www.city-data.com/city/Detroit-Michigan.html
======================================
[Y] – 11/13/2013 – The War on Cancer (I don’t think it means, what you think it says it means) #Winning?:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/11/13/httpcancer-orgacsgroupscontentepidemiologysurveilancedocumentsdocumentacspc-036845-pdf/
======================================
[Z] – 3/9/2013 – Quackademic Medicine: How pseudoscience is infiltrating medical academia.”
——————————————————————
http://m.youtube.com/watch?v=mewOSMNgfGQ&desktop_uri=%2Fwatch%3Fv%3DmewOSMNgfGQ
======================================
[]
——————————————————————
http://www.nixonlibrary.gov/forresearchers/find/tapes/excerpts/watergate.php
——————————————————————
http://whitehousetapes.net/transcript/nixon/cancer-presidency
——————————————————————
http://m.washingtonpost.com/politics/cancer-on-the-presidency/2012/06/08/gJQAp24LOV_video.html
——————————————————————
http://www.history.com/speeches/nixon-and-dean-discuss-watergate
======================================
2013-2014 Breast Cancer Facts & Figures
——————————————————————

Click to access acspc-040951.pdf

——————————————————————

Click to access acspc-040951.pdf

——————————————————————
2013-2014 Cancer Facts & Figures for African Americans
——————————————————————

Click to access acspc-036921.pdf

——————————————————————

Click to access acspc-036921.pdf

——————————————————————
2012-2014 Cancer Facts & Figures for Hispanics / Latinos
——————————————————————

Click to access acspc-034778.pdf

——————————————————————

Click to access acspc-034778.pdf

======================================
2013 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013
——————————————————————
2013-2014 Cancer Facts & Figures
——————————————————————

Click to access acspc-040951.pdf

——————————————————————

Click to access acspc-040951.pdf

——————————————————————

——————————————————————
http://onlinelibrary.wiley.com/doi/10.3322/caac.21203/full
——————————————————————
2013
——————————————————————

Click to access breast-cancer-facts-2012.pdf

——————————————————————

Click to access breast-cancer-facts-2012.pdf

——————————————————————
2012-2013 Survivorship
——————————————————————

Click to access acspc-033876.pdf

——————————————————————

Click to access acspc-033876.pdf

——————————————————————
2013 – Cancer Facts & Figures
——————————————————————

Click to access acspc-036845.pdf

——————————————————————

Click to access acspc-036845.pdf

——————————————————————
2013 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/index
======================================
2011-2012 Breast Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/breast-cancer-facts-and-figures-2011-2012
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/breast-cancer-facts-and-figures-2011-2012
——————————————————————
Breast Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/breast-cancer-facts-figures
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/breast-cancer-facts-figures
——————————————————————
2012 – Cancer Facts & Figures
——————————————————————

Click to access acspc-031941.pdf

——————————————————————

Click to access acspc-031941.pdf

——————————————————————
2012 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2012/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2012/index
——————————————————————
2012 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2012
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2012
——————————————————————
2011-2012 Cancer Facts & Figures for African Americans
——————————————————————

Click to access acspc-027765.pdf

——————————————————————

Click to access acspc-027765.pdf

======================================
2011 – Cancer Facts & Figures
——————————————————————

Click to access acspc-029771.pdf

——————————————————————

Click to access acspc-029771.pdf

——————————————————————
2011 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2011
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2011
——————————————————————
2009-2011 Cancer Facts & Figures for Hispanics / Latinos
——————————————————————

Click to access ffhispanicslatinos20092011.pdf

——————————————————————

Click to access ffhispanicslatinos20092011.pdf

======================================
2010
——————————————————————
http://cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/breast-cancer-facts-figures-2009-2010
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/breast-cancer-facts-figures-2009-2010
——————————————————————
2009-2010 Breast Cancer Facts & Figures
——————————————————————

Click to access f861009final90809pdf.pdf

——————————————————————

Click to access f861009final90809pdf.pdf

——————————————————————
2010 – Cancer Facts & Figures
——————————————————————

Click to access acspc-024113.pdf

——————————————————————

Click to access acspc-024113.pdf

——————————————————————
2010 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2010/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2010/index
——————————————————————
2009-2010 Cancer Facts & Figures for African Americans
——————————————————————

Click to access cffaa20092010pdf.pdf

——————————————————————

Click to access cffaa20092010pdf.pdf

======================================
2009
——————————————————————
http://www.komenstlouis.org/site/DocServer/DiversityAsianPacific.pdf?docID=222
——————————————————————
2009-2010 Cancer Facts & Figures for African Americans
——————————————————————

Click to access cffaa20092010pdf.pdf

——————————————————————

Click to access cffaa20092010pdf.pdf

——————————————————————
2009 – Cancer Facts & Figures
——————————————————————

Click to access 500809webpdf.pdf

——————————————————————

Click to access 500809webpdf.pdf

——————————————————————
2009 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2009/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2009/index
——————————————————————
2009 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2009
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2009
======================================
Breast Cancer Facts & Figures
——————————————————————
http://www.cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/
——————————————————————
2007-2008 Breast Cancer Facts & Figures
——————————————————————

Click to access bcfffinalpdf.pdf

——————————————————————

Click to access bcfffinalpdf.pdf

——————————————————————
Cancer Facts and Statistics
——————————————————————
http://cancer.org/research/cancerfactsstatistics/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/index
——————————————————————
2008 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
——————————————————————
2008 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2008/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2008/index
——————————————————————
2008 – Cancer Facts & Figures
——————————————————————

Click to access 2008cafffinalsecuredpdf.pdf

——————————————————————

Click to access 2008cafffinalsecuredpdf.pdf

——————————————————————
2008 – Cancer Facts & Figures
——————————————————————

Click to access worldcancer.pdf

——————————————————————

Click to access worldcancer.pdf

——————————————————————
Global
——————————————————————

Click to access acspc-027766.pdf

——————————————————————

Click to access acspc-027766.pdf

——————————————————————
2008 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2008/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2008/index
——————————————————————
Cancer Facts and Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
======================================
2007-2008 Breast Cancer Facts & Figures
——————————————————————

Click to access bcfffinalpdf.pdf

——————————————————————

Click to access bcfffinalpdf.pdf

——————————————————————

——————————————————————
http://komen.org/BreastCancer/BreastFactsReferences.html
——————————————————————

——————————————————————
http://ww5.komen.org/BreastCancer/BreastFactsReferences.html
——————————————————————
2007 – Cancer Facts & Figures
——————————————————————

Click to access caff2007pwsecuredpdf.pdf

——————————————————————

Click to access caff2007pwsecuredpdf.pdf

——————————————————————
2007 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2007/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2007/index
——————————————————————
2007 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2007
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2007
——————————————————————
2007-2008 Cancer Facts & Figures for African Americans
——————————————————————

Click to access caff2007aaacspdf2007pdf.pdf

——————————————————————

Click to access caff2007aaacspdf2007pdf.pdf

——————————————————————
2006-2008 Cancer Facts & Figures for Hispanics / Latinos
——————————————————————

Click to access caff2006hisppwsecuredpdf.pdf

——————————————————————

Click to access caff2006hisppwsecuredpdf.pdf

======================================
2006 – Cancer Facts & Figures
——————————————————————

Click to access caff2006pwsecuredpdf.pdf

——————————————————————

Click to access caff2006pwsecuredpdf.pdf

——————————————————————
2006 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2006
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2006
——————————————————————
2005-2006 Breast Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/breast-cancer-facts–figures-2005-2006
——————————————————————
2005-2006 Breast Cancer Facts & Figures
——————————————————————

Click to access caff2005brfacspdf2005pdf.pdf

——————————————————————

Click to access caff2005brfacspdf2005pdf.pdf

——————————————————————
2005-2006 Breast Cancer Facts & Figures
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/breast-cancer-facts–figures-2005-2006
——————————————————————
2005-2006 Cancer Facts & Figures for African Americans
——————————————————————

Click to access caff2005aacorrpwsecuredpdf.pdf

——————————————————————

Click to access caff2005aacorrpwsecuredpdf.pdf

======================================
2005 – Cancer Facts & Figures
——————————————————————

Click to access caff2005f4pwsecuredpdf.pdf

——————————————————————

Click to access caff2005f4pwsecuredpdf.pdf

——————————————————————

——————————————————————
http://worldwidebreastcancer.com/learn/breast-cancer-statistics-worldwide/
——————————————————————

——————————————————————
http://www.worldwidebreastcancer.com/learn/breast-cancer-statistics-worldwide/
——————————————————————
Cancer Facts and Figures
——————————————————————
http://cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
——————————————————————
2005 – Cancer Facts & Figures
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2005
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2005
======================================
2003-2004 Breast Cancer Facts & Figures
——————————————————————

Click to access caff2003brfpwsecuredpdf.pdf

——————————————————————

Click to access caff2003brfpwsecuredpdf.pdf

——————————————————————
2004 – Cancer Facts & Figures
——————————————————————

Click to access CancerRates2004.pdf

======================================
2003
——————————————————————
http://cancer.org/cancer/breastcancer/detailedguide/breast-cancer-references
——————————————————————
http://m.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-references
——————————————————————
2003 – Cancer Facts & Figures
——————————————————————

Click to access 2003_ACS_Cancer_Facts.pdf

======================================
2002 – American Cancer Society Cancer Facts & Figures
——————————————————————

Click to access acspc-027766.pdf

——————————————————————

Click to access acspc-027766.pdf

——————————————————————
2002 – Cancer Facts & Figures
——————————————————————

Click to access CancerFacts&Figures2002.pdf

======================================

Advertisement

Turkey Lurkey Thanksgiving Title

Traditionally, Thanksgiving is best known as the Holiday that the Detroit Lions get the “stuffing” knocked out of them

However, this year, it’s time to tender the tainted twisted trophy of Thanksgiving Turkey-Lurkey to Detroit’s toasted triumvirate treat of two-faced twerk-salad troll turpitude, and I have the temerity to tinker and tamper until I pay tribute with therapeutic levels of Thoreauness in response to GorskGeek’s misinformation, disinformation, and MisDisInformation (Missed ‘Dis Information)

Wednesday, 12/21/2005, Indianapolis, Indiana-based Eli Lilly and Company was treated to truthification, in connection with their illegal promotion (misbranding) of pharmaceutical drug EVISTA; (FDA approved for prevention and treatment of osteoporosis in post-menopausal women), in the:

a. prevention in risk of breast cancer

b. reduction in risk of breast cancer

Alleged in information, promoted drug as effective for reducing risk of breast cancer EVEN AFTER PROPOSED LABELING FOR THIS USE SPECIFICALLY REJECTED by FDA [1]

GorskGeek, being the breast cancer oncology specialist he claims to be, and so concerned about breast cancer patients that he is that “guy” who speaks out passionately about issues like the 10-year American Cancer Society Cancer Facts & Figures, “Estimated Breast Cancer Deaths for Women”, which reflect that in 2002, 39,600 (15%) women were estimated to die from breast cancer, and this year, 2013, the estimate is 39,620 (14%), which is 20 women MORE than 10-years ago, and who rails tirelessly about the ACS’s “Estimated New Breast Cancer cases in Women”, which 10-years ago was 203,500 (31%) in 2002, and now, in 2013 is 232,340 (29%), which is ONLY
28,840 MORE than 10-years ago [2]

Now THAT’s progress !

GorskGeek, of course, must accomplish all this under his breath

But I’m sure you’re wondering, dear reader, what was GorskGeek’s outraged blog about this American pharmaceutical manufacturer coughing up $36 MILLION ?

Well, let me tell you … just as soon as I find it

Wait for it

Wait for it

Wait for it

GorskGeek was unable to bring himself to blog about Evista until exactly one year later, on 12/21/2006, and even then, he was “mum’s the word” about the breast cancer claims [3]

Perhaps GorskGeek just “knew” that eventually Evista would finally be approved by the FDA for Eli Lilly’s preventing or reducing risk of breast cancer claims on 9/13/2007, and who were those paper-pushing FDA apparatchiks to prevent Lilly from implementing their “Internal business plan” ? [4-9]

GorskGeek wouldn’t want to damage his slim and non-existent chance of getting some Eli Lilly money for research, by blogging anything that might in any way be possibly construed as him saying anything negatory about the BIG Pharma teat he longs to suck off of

After all, Bob ‘n’ Weave Blaskiewicz (who sees every molehill as a mountain), did say about GorskGeek, 9/28/2013 [10]:
——————————————————————
1:58:04
——————————————————————
“But he is a, the thing is, the thing is, you thing you have to understand is Gorski, Gorski is a genuine expert, in matters re re regarding on oncology studies“

“I mean, he has a”

“He, He’s able to convince people, he’s able to convince people, on the strength of his record, to give him money to carry out research”

“People who know what they’re talking about”

“To give him money to carry out his research”

“Right ?”
——————————————————————
1:59:00
——————————————————————
Yeah, right

Bobby 🙂

GorskGeek is hoping for a Happy Thanksgiving Golden Parachute; which is where he helps whistleblow about illegal BIG Pharma activity regarding some drug(s), which leaves him as the beneficiary of some funds like Mr. H. Dean Steinke, former Merck employee and his $68,190,000 MILLION from the federal government and states share of settlement amounts:
——————————————————————
$44,690,000 MILLION – Mr. H. Dean Steinke, former Merck employee from federal share of settlement amount (1997 – 2001)
——————————————————————
$23.5 MILLION – Mr. H. Dean Steinke, former Merck employee from the states share of settlement amount (1997 – 2001)
——————————————————————
Next, GorskGeek goes off on his fave autism prescription antipsychotic drug Risperdal, and the 11/4/2013, Monday, allegations concerning Global health care giant Johnson & Johnson (J&J) and its subsidiaries, $2.2 BILLION + fine regarding J&J Subsidiary Janssen (1999 – 2005) actions [11]
======================================
REFERENCES:
======================================
[1] – 12/21/2005
——————————————————————
EVISTA (FDA approved for prevention and treatment of osteoporosis in post-menopausal women)
——————————————————————
Eli Lilly and Company, Indianapolis, Indiana-based company
——————————————————————
12/21/2005, Wednesday
——————————————————————
$36 MILLION
——————————————————————
In connection with illegal promotion of pharmaceutical drug
——————————————————————
Pleading guilty to criminal count of violating Food, Drug, and Cosmetic Act by misbranding drug
——————————————————————
In addition to criminal plea
agreed to settle civil Food, Drug, and Cosmetic Act liabilities by entering into consent decree of permanent injunction
——————————————————————
Charged in criminal information filed with violation of Food, Drug, and Cosmetic Act, following investigation by Food and Drug Administration’s (FDA) Office of Criminal Investigations
——————————————————————
Plea agreement signed by Lilly and United States

Complaint for permanent injunction

Consent decree of permanent injunction signed by company and United States
——————————————————————
Information alleges 1st year’s sales of drug in U.S. were disappointing compared to original forecast
——————————————————————
According to information
10/1998 – company reduced forecast of drug’s 1st year’s sales in U.S. from $401 million to $120 million
——————————————————————
Internal business plan noted:

“Disappointing year versus original forecast.”
——————————————————————
Information alleges in order to expand sales of drug, Lilly sought to broaden market for drug by promoting it for unapproved uses
——————————————————————
Information alleges strategic marketing plans and promotion touted drug as effective in preventing and reducing risk of diseases for which drug’s labeling lacked adequate directions for use
——————————————————————
According to information: Evista
1. brand team
2. sales representatives
promoted drug for:
a. prevention in risk of breast cancer
b. reduction in risk of breast cancer
c. reduction in risk of cardiovascular disease
——————————————————————
Under provisions of Food, Drug, and Cosmetic Act, drug misbranded when labeling didn’t bear adequate directions for each of intended uses
——————————————————————
Alleged in information, promoted drug as effective for reducing risk of breast cancer even after proposed labeling for this use specifically rejected by FDA
——————————————————————
Information alleges executed illegal conduct using number of tactics, including:

1. One-on-one sales pitches by sales representatives promoting drug to physicians about off-label uses of drug

2. Sales representatives trained to prompt or bait questions by doctors in order to promote drug for unapproved uses

3. Encouraging sales representatives promoting drug to send unsolicited medical letters to promote drug for unapproved use to doctors on their sales routes

4. Organizing “market research summit’ during which drug was discussed with physicians for unapproved uses, including reducing risk of breast cancer

5.
a. Creating
b. distributing
to sales representatives “Evista Best Practices” videotape, in which sales representative states “Evista truly is the best drug for the prevention of all these diseases” referring to:

1). osteoporosis
2). breast cancer
3). cardiovascular disease
——————————————————————
Complaint for permanent injunction alleges executed illegal conduct using number of tactics, including:

1. Training sales representatives to promote drug for prevention and reduction in risk of breast cancer by use of medical reprint in way that highlighted key results of drug and thereby promoted drug to doctors for unapproved use

2. Some sales representatives were instructed to hide disclosure page of reprint which noted:

a. “All of the authors were either employees or paid consultants of Eli Lilly at the time this article was written,”

b. “The prescribing information provides that “The effectiveness of [Evista] in reducing the risk of breast cancer has not yet been established.””

3. Organizing “consultant meetings” for physicians who prescribed drug during which unapproved uses of drug discussed

4. Calculating incremental new prescriptions for doctors who attended Evista advisory board meetings in 1998

5. advisory board meetings included discussion of unapproved uses for drug

6. By measuring and analyzing incremental new prescriptions for doctors who attended advisory board meetings, Lilly was using this intervention as tool to promote and sell drug
——————————————————————
In addition to agreeing to plead guilty to criminal information and plea agreement signed by Lilly, settlement with United States includes following components:

(a) agreed to settle civil Food, Drug, and Cosmetic Act liabilities by entering into consent decree of permanent injunction

(1). As part of consent decree, agreed to comply with terms of permanent injunction, which will require company to implement effective training and supervision of marketing and sales staff for drug, and ensure any future off-label marketing conduct is detected and corrected

(2). agreed to be permanently enjoined from directly or indirectly promoting drug for use in:

a. preventing or reducing risk of breast cancer

b. reducing risk of cardiovascular disease

c. or for any other unapproved use in manner that violates Food, Drug, and Cosmetic Act unless and until FDA approves drug for additional use or uses
——————————————————————
(b) as part of consent decree, agreed to hire and utilize independent organization to conduct reviews to assist Lilly in assessing and evaluating Lilly’s

1. systems
2. processes
3. policies
4. procedures
relating to promotion of drug and company’s compliance with consent decree
——————————————————————
FDA made following announcement to postmenopausal women who have taken drug for prevention or treatment of osteoporosis:
——————————————————————
“No postmenopausal woman who has taken Evista for the prevention or treatment of osteoporosis is affected by this action, as this matter today relates only to unapproved uses of Evista.”
——————————————————————
Defendant agreed to plead guilty to charge in information
——————————————————————
Defendant agreed to resolve complaint for permanent injunction by agreeing to consent decree of permanent injunction
——————————————————————
http://www.justice.gov/opa/pr/2005/December/05_civ_685.html
======================================
[2] – 11/13/2013 – The War on Cancer (I don’t think it means, what you think it says it means) #Winning?:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/11/13/httpcancer-orgacsgroupscontentepidemiologysurveilancedocumentsdocumentacspc-036845-pdf/
======================================
[3] – 12/21/2006 – On the messiness of evidence-based medicine
——————————————————————
http://scienceblogs.com/insolence/2006/12/21/the-messiness-of-evidencebased-medicine/
======================================
[4] – 9/13/2007 – FDA Approval for Raloxifene Hydrochloride (Brand name(s): Evista®): Approved for breast cancer risk reduction:
——————————————————————
http://www.cancer.gov/cancertopics/druginfo/fda-raloxifene-hydrochloride
======================================
[5] – 9/14/2007 – FDA Approves New Uses for Evista: Drug Reduces Risk of Invasive Breast Cancer in Postmenopausal Women:
——————————————————————
http://www.fda.gov/newsevents/newsroom/pressannouncements/2007/ucm108981.htm
======================================
[6] – 9/17/2007 – Evista Approved for Reducing Breast Cancer Risk:
——————————————————————
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm048474.htm
======================================
[7] – 2007
——————————————————————

Click to access 020815s018lbl.pdf

======================================
[8]
——————————————————————

Click to access ucm088593.pdf

======================================
[9] – 2007
——————————————————————

Click to access 022042lbl.pdf

======================================
[10] – 10/18/2013 – Deconstructing Dr. David H. (Orac) Gorski – September 28, 2013 “The Skeptics™” Burzynski discussion: By Bob Blaskiewicz – 2:19:51
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/10/18/deconstructing-dr-david-h-orac-gorski-september-28-2013-the-skeptics-burzynski-discussion-by-bob-blaskiewicz-21951/
======================================
[11] – 11/4/2013
——————————————————————
http://www.justice.gov/opa/pr/2013/November/13-ag-1170.html
======================================

Cancer: Leading Causes of Death: Death Rates, Leading Causes of Death Among Minority Groups, U.S., National Institutes of Health (NIH) National Heart, Lung, and Blood Institute 2005-2012 (2002-2010)

——————————————————————
Source: Vital Statistics of the United States, NCHS
======================================
Cancer (2nd) – Leading Causes of Death: Death Rates, U.S. Per 100,000
——————————————————————
2010☝186.2 (2012)
2008👇186 (2011)
2007☝ 186.6 (2010)
2007*👇185.7 (2009)
2006*👇187.1 (2008)
2005*☝188.7 (2007)
2004👇168.6 (2006)
2003☝189.3 (2005)
======================================
Leading Causes of Death Among Minority Groups, U.S.: Cancer
——————————————————————
Black – Percent of All Deaths
——————————————————————
2010☝23% (2nd highest, behind heart: 24.1%) (2012)
2008 – 22.1% (2nd highest, behind heart: 24.5%) (2011)
2007☝22.1% (2nd highest, behind heart: 24.6%) (2010)
2006☝21.75% (2nd highest, behind heart: 24.92%) (2009)
2005👇21.6% (2nd highest, behind heart: 25.3%) (2008)
2004☝21.8% (2nd highest, behind heart: 25.8%) (2007)
2003☝21.5% (2nd highest, behind heart: 26.6%) (2006)
2002☝21% (2nd highest, behind heart: 27%) (2005)
——————————————————————
Hispanic – Percent of All Deaths
——————————————————————
2010☝21.5% – (highest) (2012)
2008👇20.7% (2nd highest, behind heart: 20.8%) (2011)
2007☝20.8% (2nd highest, behind heart: 21.8%) (2010)
2006☝20.02% (2nd highest, behind heart: 21.74%) (2009)
2005👇19.9% (2nd highest, behind heart: 22.5%) (2008)
2004☝20% (2nd highest, behind heart: 22.7%) (2007)
2003 – 19.7% (2nd highest, behind heart: 23.2%) (2006)
2002☝19.7% (2nd highest, behind heart: 23.9%) (2005)
——————————————————————
Asian* – Percent of All Deaths – * Includes deaths among individuals of Asian extraction and Asian-Pacific Islanders
——————————————————————
2010👇27.70% – (highest) (2012)
2008☝28.7% (highest, before heart: 24.8%) (2011)
2007☝27.6% (highest, before heart: 23.6%) (2010)
2006☝26.36% (highest, before heart: 23.87%) (2009)
2005👇25.7% (highest, before heart: 24.2%) (2008)
2004☝26.8% (highest, before heart: 24.6%) (2007)
2003☝26.2% (highest, before heart: 25.3%) (2006)
2002☝25.4% (2nd highest, behind heart: 26.4%) (2005)
——————————————————————
American Indian** – Percent of All Deaths – ** Includes deaths among Aleuts and Eskimos
American Indian/Alaska Native
——————————————————————
2010☝19% – (highest) (2012)
2008☝18.5 (highest, before heart: 18.%) (2011)
2007☝18.2% (2nd highest, behind heart: 18.9%) (2010)
2006👇17.43% (2nd highest, behind heart: 19.49%) (2009)
2005👇17.7% (2nd highest, behind heart: 19.1%) (2008)
2004☝18.2% (2nd highest, behind heart: 19.8%) (2007)
2003👇16.4% (2nd highest, behind heart: 20.6%) (2006)
2002☝18% (2nd highest, behind heart: 20.1%) (2005)
======================================
REFERENCES:
======================================
2010 (2012):
——————————————————————
http://www.nhlbi.nih.gov/about/factpdf.htm
——————————————————————
http://www.nhlbi.nih.gov/about/factbook/toc.htm
——————————————————————

Click to access FactBook2012.pdf

——————————————————————
2010 – Black (2012):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook/chapter4data.htm#gr9-121
——————————————————————
2010 – Hispanic (2012):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook/chapter4data.htm#gr9-122
——————————————————————
2010 – Asian/Pacific Islander (2012):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook/chapter4data.htm#gr9-123
——————————————————————
2010 – American Indian/Alaska Native (2012):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook/chapter4data.htm#gr9-124
======================================
2005-2011 Archive (2002-2009):
——————————————————————
http://www.nhlbi.nih.gov/about/factpdf_archive.htm
======================================
2011 – Fiscal Year – NHLBI Fact Book Archive (2008-2009):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-11/chapter4.htm
——————————————————————
PDF:
——————————————————————

Click to access FactBook_2011.pdf

——————————————————————
HTML/Web Version (Accessible version, recommended for screen readers)
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-11/toc.htm
——————————————————————
2008 – Leading Causes of Death: Death Rates, U.S. (2011):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-11/chapter4data.htm#gr8
——————————————————————
2008 – Black (2011):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-11/chapter4data.htm#gr9-121
——————————————————————
2008 – Hispanic (2011):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-11/chapter4data.htm#gr9-122
——————————————————————
2008 – Asian (2011):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-11/chapter4data.htm#gr9-123
——————————————————————
2008 – American Indian (2011):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-11/chapter4data.htm#gr9-124
======================================
2010 – Fiscal Year – NHLBI Fact Book (2007-2008):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-10/chapter4.htm
——————————————————————
PDF:
——————————————————————

Click to access FactBook_2010.pdf

——————————————————————
HTML/Web Version (Accessible version, recommended for screen readers)
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-10/toc.htm
——————————————————————
2007 – Leading Causes of Death: Death Rates, U.S. (2010):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-10/chapter4data.htm#gr8
——————————————————————
2007 (2010):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-10/chapter4data.htm#gr9-121
——————————————————————
2007 – Black (2010):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-10/chapter4data.htm#gr9-121
——————————————————————
2007 – Hispanic (2010):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-10/chapter4data.htm#gr9-122
——————————————————————
2007 – Asian (2010):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-10/chapter4data.htm#gr9-123
——————————————————————
2007 – American Indian (2010):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-10/chapter4data.htm#gr9-124
======================================
2009 – Fiscal Year – NHLBI Fact Book (2006-2007):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-09/chapter4.htm
——————————————————————
PDF:
——————————————————————

Click to access FactBook2009_final.pdf

——————————————————————
HTML/Web Version (Accessible version, recommended for screen readers):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-09/toc.htm
——————————————————————
2007* – Leading Causes of Death: Death Rates, U.S., *Data for 2007 are preliminary (2009):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-09/chapter4data.htm#gr8
——————————————————————
2006 – Leading Causes of Death Among Minority Groups, U.S. (2009):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-09/chapter4.htm
——————————————————————
2006 – Black (2009):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-09/chapter4data.htm#gr9-121
——————————————————————
2006 – Hispanic (2009):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-09/chapter4data.htm#gr9-122
——————————————————————
2006 – Asian (2009):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-09/chapter4data.htm#gr9-123
——————————————————————
2006 – American Indian (2009):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-09/chapter4data.htm#gr9-124
======================================
2008 – Fiscal Year – NHLBI Fact Book (2005-2006):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-08/chapter4.htm
——————————————————————
PDF:
——————————————————————

Click to access FactBookFinal.pdf

——————————————————————
HTML/Web Version (Accessible version, recommended for screen readers):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-08/toc.htm
——————————————————————
2006* – Leading Causes of Death: Death Rates, U.S., *Data for 2006 are preliminary (2008):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-08/chapter4.htm#gr8
——————————————————————
2005 – Leading Causes of Death Among Minority Groups, U.S. (2008):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-08/chapter4.htm
——————————————————————
2005 – Leading Causes of Death Among Minority Groups, U.S. (2008):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-08/chapter4.htm
——————————————————————
2005 – Black (2008):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-08/chapter4data.htm#gr9-121
——————————————————————
2005 – Hispanic (2008):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-08/chapter4data.htm#gr9-122
——————————————————————
2005 – Asian (2008):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-08/chapter4data.htm#gr9-123
——————————————————————
2005 – American Indian (2008):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-08/chapter4.htm
======================================
2007 – Fiscal Year – NHLBI Fact Book (2004-2005):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-07/chapter4.htm
——————————————————————
PDF:
——————————————————————

Click to access 07factbk.pdf

——————————————————————
HTML/Web Version (Accessible version, recommended for screen readers):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-07/toc.htm
——————————————————————
2005* – Leading Causes of Death: Death Rates, U.S., *Data for 2005 are preliminary (2007):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-07/chapter4data.htm#gr8
——————————————————————
2004 – Leading Causes of Death Among Minority Groups, U.S. (2007):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-07/chapter4.htm
——————————————————————
2004 – Black (2007):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-07/chapter4data.htm#gr9-121
——————————————————————
2004 – Hispanic (2007):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-07/chapter4.htm#gr9-124
——————————————————————
2004 – Asian (2007):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-07/chapter4data.htm#gr9-123
——————————————————————
2004 – American Indian (2007):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-07/chapter4data.htm#gr9-124
======================================
2006 – Fiscal Year – NHLBI Fact Book (2003-2004):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-06/chapter4.htm
——————————————————————
PDF:
——————————————————————

Click to access 06factbk.pdf

——————————————————————
HTML/Web Version (Accessible version, recommended for screen readers):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-06/toc.htm
——————————————————————
2004 – Leading Causes of Death: Death Rates, U.S. (2006):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-06/chapter4data.htm#gr8
——————————————————————
2003 – Leading Causes of Death Among Minority Groups, U.S. (2006):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-06/chapter4.htm#gr9-12
——————————————————————
2003 – Black (2006):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-06/chapter4data.htm#gr9-12
——————————————————————
2003 – Hispanic (2006):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-06/chapter4data.htm#gr9-12
——————————————————————
2003 – Asian (2006):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-06/chapter4data.htm#gr9-12
——————————————————————
2003 – American Indian (2006):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-06/chapter4data.htm#gr9-12
======================================
2005 – Fiscal Year – NHLBI Fact Book (2002-2003):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-05/chapter4.htm
——————————————————————
PDF:
——————————————————————

Click to access 05factbk.pdf

——————————————————————
HTML/Web Version (Accessible version, recommended for screen readers):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-05/toc.htm
——————————————————————
2003 – Leading Causes of Death: Death Rates, U.S. (2005):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-05/chapter4data.htm#gr8
——————————————————————
2002 – Leading Causes of Death Among Minority Groups, U.S. (2005):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-05/chapter4data.htm#gr9-12
——————————————————————
2002 – Black (2005):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-05/chapter4data.htm#gr9-12
——————————————————————
2002 – Hispanic (2005):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-05/chapter4data.htm#gr9-12
——————————————————————
2002 – Asian (2005):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-05/chapter4data.htm#gr9-124
——————————————————————
2002 – American Indian (2005):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-05/chapter4data.htm#gr9-12
======================================

Count de Money: What Are the Costs of Cancer ? (American Cancer Society Cancer Facts & Figures 2002-2013)

======================================
What Are the Costs of Cancer?
——————————————————————
National Institutes of Health (NIH) estimates:
——————————————————————
overall costs of cancer:
——————————————————————
2010 – $263.8 billion (2011)
2010☝$263.8 billion (2010)
2008👇$201.5 billion (2013)
2008☝$228.1 billion (2009)
2007☝$226.8 billion (2012)
2007☝$219.2 billion (2008)
2006👇$206.3 billion (2007)
2005☝$209.9 billion (2006)
2004☝$189.8 billion (2005)
2003☝$189.5 billion (2004)
2002☝$171.6 billion (2003)
2001☝$156.7 billion (2002)
——————————————————————
direct medical costs
(total of all health expenditures)
——————————————————————
2010 – $102.8 billion (2011)
2010☝$102.8 billion (2010)
2008👇$77.4 billion (2013)
2008👇$93.2 billion (2009)
2007☝$103.8 billion (2012)
2007☝$89.0 billion (2008)
2006☝$78.2 billion (2007)
2005☝$74.0 billion (2006)
2004☝$69.4 billion (2005)
2003☝$64.2 billion (2004)
2002☝$60.9 billion (2003)
2001☝$56.4 billion (2002)
——————————————————————
2008-2011 – indirect morbidity costs
(cost of lost productivity due to illness)
——————————————————————
2010 – $20.9 billion (2011)
2010☝$20.9 billion (2010)
2008☝$18.8 billion (2009)
2007☝$18.2 billion (2008)
2006☝$17.9 billion (2007)
2005☝$17.5 billion (2006)
2004☝$16.9 billion (2005)
2003☝$16.3 billion (2004)
2002👇$15.5 billion (2003)
2001☝$15.6 billion (2002)
——————————————————————
indirect mortality costs
(cost of lost productivity due to premature death)
——————————————————————
2010 – $140.1 billion (2011)
2010☝$140.1 billion (2010)
2008☝$124.0 billion (2013)
2008👇$116.1 billion (2009)
2007☝$123.0 billion (2012)
2007☝$112.0 billion (2008)
2006👇$110.2 billion (2007)
2005☝$118.4 billion (2006)
2004👇$103.5 billion (2005)
2003☝$109 billion (2004)
2002☝$95.2 billion (2003)
2001☝$84.7 billion (2002)
——————————————————————
According to US Census Bureau:
——————————————————————
Americans uninsured
2012-2013 had no health insurance coverage
——————————————————————
2010👇approximately 50 million (2013)
2009 – almost 51 million (2012)
2009☝almost 51 million (2011)
2008☝46 million (2010)
——————————————————————
2008 – approximately 28% aged 18 to 34 years (2010)
——————————————————————
2010👇almost one-third of Hispanics (31%) (2013)
2009 – almost one-third of Hispanics (32%) (2012)
2009☝almost one­-third of Hispanics (32%) (2011)
——————————————————————
2011-2012 (17 years of age and younger)
2010-2012 – had no health insurance coverage
——————————————————————
2010 – one in 10 children (2013)
2009 – one in 10 children (2012)
2009 – one in 10 children (2011)
2008 – 10% of children (2010)
——————————————————————
2012-2013 PLEASE NOTE:

These numbers are not comparable to those published in previous years as of 2011, NIH calculating estimates using different data source:

2012 – NIH is using a different data source:

2012-2013 Medical Expenditure Panel Survey (MEPS) of the Agency for Healthcare Research and Quality

2012-2013 MEPS estimates based on more current, nationally representative data used extensively in scientific publications

2012-2013 direct and indirect costs will no longer be projected to current year, estimates of indirect morbidity costs discontinued

2012-2013 For more information, please visit nhlbi.nih.gov/about/factpdf.htm.
——————————————————————
Lack of health insurance and other barriers prevents many Americans from receiving optimal health care
——————————————————————
2008 – early release estimates from National Health Interview Survey (2009)
2006 – early release estimates from the National Health Interview Survey (2008)
2004 – National Health Interview Survey data (2007)
2003 – National Health Interview Survey data (2006)
——————————————————————
2008 – about 24% aged 18 to 64 years (2009)
2006☝about 24% aged 18-64 (2008)
2004 – about 17% younger than age 65 had no health insurance coverage (2007)
2003☝about 17% younger than age 65 have no health insurance coverage (2006)
——————————————————————
2004 – 27% 65 and older had Medicare coverage only (2007)
2003☝24% 65 and older have Medicare coverage only (2006)
——————————————————————
2008 – 13% of children had no health insurance coverage for at least part of past year (2009)
2006☝13% of children had no health insurance coverage for at least part of past year (2008)
——————————————————————
2008 – More than 36% of adults who lack high school diploma were uninsured in past year (2009)
2006☝Almost 34% of adults who lack high school diploma were uninsured in past year (2008)
——————————————————————
2008 – 23% of high school graduates (2009)
2006☝23% of high school graduates (2008)
——————————————————————
2008👇14% of those with more than high school education (2009)
2006 – 15% of those with more than high school education (2008)
——————————————————————
2008 – Lack of health insurance is not only a concern of unemployed; almost one-quarter of employed individuals (aged 18 to 64 years) were uninsured sometime during past year (2009)
——————————————————————
2004 – Persons in lowest income group 10 times as likely as persons in highest income group not to receive needed medical care because of cost (2007)
——————————————————————
2004 – Almost 16 million citizens (6%) were unable to obtain needed medical care due to cost (2007)
——————————————————————
2003 – In survey, nearly 20% aged 18-44 years reported not having usual place to go for medical care (2006)
——————————————————————
2010-2013 – Uninsured patients and ethnic minorities substantially more likely to be diagnosed with cancer at later stage, when treatment can be more extensive and more costly
——————————————————————
2012-2013 – For more information on relationship between health insurance and cancer, see Cancer Facts & Figures 2008, Special Section, available online at cancer.org/statistics.
2010 – cancer.org.
2009 – (5008.08), Special Section, available online at cancer.org.
2008 – see special section page 22

======================================
REFERENCES:
======================================
2013:
——————————————————————

Click to access acspc-036845.pdf

======================================
2012:
——————————————————————

Click to access acspc-031941.pdf

======================================
2011:
——————————————————————

Click to access acspc-029771.pdf

======================================
2010:
——————————————————————

Click to access acspc-024113.pdf

======================================
2009:
——————————————————————

Click to access 500809webpdf.pdf

======================================
2008:
——————————————————————

Click to access worldcancer.pdf

=====================================
2007:
——————————————————————

Click to access caff2007pwsecuredpdf.pdf

======================================
2006:
——————————————————————

Click to access caff2006pwsecuredpdf.pdf

======================================
2005:
——————————————————————

Click to access caff2005f4pwsecuredpdf.pdf

======================================
2004:
——————————————————————

Click to access CancerRates2004.pdf

======================================
2003:
——————————————————————

Click to access 2003_ACS_Cancer_Facts.pdf

======================================
2002:
——————————————————————

Click to access CancerFacts&Figures2002.pdf

======================================

Critiquing: Doctor accused of selling false hope to families (USA TODAY NEWS, NATION, Liz Szabo, USA TODAY)

I gave Liz Szabo and USA TODAY the chance to act like a Spike Lee joint and “Do the Right Thing”, the same day their article came out [1]

I gave them the opportunity to prove that their article was a legitimate piece of journalism with some semblance of integrity, and NOT just akin to one of “The Skeptics™ phoned-in “rubber-stamped” yellow journalism hit pieces

Instead, it seems that Liz Szabo and / or USA TODAY decided to act as if they had rolled a Spike Lee joint

I sent an e-mail with 2 editorial corrections, and only one (correcting Lisa Merritt’s comment
link from taking the reader to the 1999 Mayo Clinic report instead of to her comments), was corrected [2]

The 2nd correction which they #FAILED to do, earns them well deserved INSOLENCE
——————————————————————
The article claims:
——————————————————————
“Burzynski, 70, calls his drugs “antineoplastons” and says he has given them to more than 8,000 patients since 1977.”
——————————————————————

——————————————————————
However, if you select the “8,000 patients” link, the referenced page does NOT indicate that at all [2]
——————————————————————

——————————————————————
It advises:
——————————————————————
“That same year, Dr. Burzynski founded his clinic in Houston where he’s since treated over 8,000 patients.” [3]
——————————————————————

——————————————————————
Nowhere does it indicate that he “treated 8,000 patients” with antineoplastons
——————————————————————

——————————————————————
The question that Liz Szabo and USA TODAY should answer, is:

1. Who is your “fact-checker”, and
2. are they smarter than a 5th grader ?
——————————————————————
In fact, Burzynski’s 2002 Securities and Exchange Commission (SEC) filing advises:

” … in 1997, his medical practice was expanded to include traditional cancer treatment options such as chemotherapy, gene targeted therapy, immunotherapy and hormonal therapy in response to FDA requirements that cancer patients utilize more traditional cancer treatment options in order to be eligible to participate in the Company’s Antineoplaston clinical trials” [4]
——————————————————————
The article continues:
——————————————————————
“Individual success stories can be misleading, said Arthur Caplan, a professor and head of the division of bioethics at NYU Langone Medical Center”
——————————————————————
The question Arthur Caplan should be asking is:

Why has the United States Food and Drug Administration required Burzynski’s clinical trial patients to fail conventional therapies; such as surgery, chemotherapy, and radiation, BEFORE they are allowed to be treated with antineoplaston therapy ?

If the F.D.A. did NOT impose these restrictions upon Burzynski’s clinical trials, then the question Arthur Caplan raises would be moot
——————————————————————
The article quotes Dr. Jan Buckner as saying:
——————————————————————
“When I hear a story that is way out of the norm, the first question I ask is,

‘OK, is the diagnosis even correct?‘ ”

“Buckner said”

“If the diagnosis wasn’t right to start with, it doesn’t matter what the treatment was.”

“Brain tumors are notoriously difficult to diagnose, Buckner says”

“When dealing with rare brain cancer, doctors may disagree about how to interpret imaging results up to 40% of the time”
——————————————————————
I wonder if Dr. Jan Buckner would agree with David Gorski; who is a BREAST cancer oncology specialist, and NOT a BRAIN cancer oncology specialist, who has the presumptiveness to speculate that 3 different medical opinions could have misdiagnosed Tori Moreno in August 1998; who was diagnosed with a very large tumor, about 3 inches in the largest diameter and located in the brain stem, which was too risky for surgery, and about which her parents were told by ALL 3, that Tori’s brain cancer was fatal and, she would die in a few days or at the most, 2-6 weeks, and that there was nothing that could be done, and was finally put on Burzynski’s antineoplaston therapy in October, when she was about 3 ½ months old, and in such condition that they were afraid that she might die at any time, David H. Gorski, M.D., Ph.D., FACS; who claims, “I do know cancer science” , has the audacity, because of his “book learnin'” has the temerity to postulate his “science-based medicine theory” that Miller’s Children at Long Beach Memorial misdiagnosed Tori Moreno’s inoperable stage 4 BSG

David Gorski has the gall to profer that City of Hope misdiagnosed Tori Moreno’s inoperable stage 4 brain stem glioma

David Gorski has the chutzpah to pontificate that Dr. Fred Epstein in New York misdiagnosed Tori Moreno’s inoperable stage IV brainstem glioma [5]
——————————————————————
The article then quotes Peter Adamson, chair of the Children’s Oncology Group:
——————————————————————
“But these therapies may have delayed benefits, taking weeks or months to shrink a tumor“

“So patients treated by Burzynski may credit him for their progress, just because he was the last doctor to treat them, says Peter Adamson, chair of the Children’s Oncology Group, an NCI-supported research network that conducts clinical trials in pediatric cancer“

“Conventional cancer treatment can also cause tumors to swell temporarily, due to inflammation“

“A patient who isn’t familiar with this phenomenon may assume her tumor is growing“

“When that swelling subsides, patients may assume it’s because of Burzynski, Adamson says”
——————————————————————
This is laughable

In support of this “phenomenon” , the article provides a link to a Canadian web-site [6]

The site posits:
——————————————————————
“RT/TMZ is now widely practiced and the standard of care for appropriately selected patients, we are learning more about the consequences of RT/TMZ”

“One phenomena, termed Pseudo-Progression (psPD)…”
——————————————————————
The problem is that this only applies to “Glioblastoma Multiforme (GBM)”, and the article provides NO proof whatsoever, that any of Burzynski’s “Glioblastoma Multiforme (GBM)” patients have taken “RT/TMZ”
——————————————————————
Additionally, the site cites the reference as:

Sanghera, Perry, Sahgal, et al., “Sunnybrook Health Sciences Odette Cancer Centre” (in press, Canadian Journal of Neuroscience)

(“In press” refers to journal articles which have been accepted for publication, but have not yet been published)

However, the journal article in question was published 1/2010, so it has NOT been “in press” for over 3 years and 7 months [7]

Get your act together, aye, Canada !
——————————————————————
The article rants and raves on and on about FDA inspection reports from as far back as 1998, but at least they did quote Richard A. Jaffe:

“In Burzynski’s defense, Jaffe notes that inspection reports represent preliminary findings”

“The FDA has not yet issued final conclusions”
——————————————————————
The article posts this ridiculous claim:
——————————————————————
“Yet the National Cancer Institute says there is no evidence that Burzynski has cured a single patient, or even helped one live longer“
——————————————————————
That’s NOT what this seems to suggest [8]
——————————————————————
Then the article quotes pediatric oncologist Peter Adamson, a professor of pediatrics and pharmacology at Children’s Hospital of Philadelphia, in what will no doubt soon be known as a “classic”:
——————————————————————
“He’s a snake oil salesman,” says pediatric oncologist Peter Adamson, a professor of pediatrics and pharmacology at Children’s Hospital of Philadelphia”
——————————————————————
All I’d like to know is, which rock did this clown crawl out from under ?

Dr. Adamson, please advise which “snake oil” has been granted Orphan Drug Designation (“ODD”) from the United States Food and Drug Administration [9], and which “snake oil” has been approved for, and used in, phase III clinical trials ? [10]
——————————————————————
Q: Is it, it the phase 2 trial is finished ?

A: “Mhmm”

Q: but they’re still accepting people ?

A: “Yeah”

Q: on more like a special ?

A: “Special basis, and, um, sometimes compassionate grounds“

A: “(compassion exception)”

A: “Uh, exceptions“

Q: That’s normal ?

A: “Yes”
“So”

A: “(Yes I guess it is a funding issue ?)”

Q: Right

A: “(Like FDA, during the 2nd phase of clinical trials they found the data to be, real, real one, and they gave him the ok to go for 3rd phase of clinical trials, but just to go through this process you would probably need $100,000)”
——————————————————————

——————————————————————
Oh, wait !!

Dr. Adamson, when you say “snake oil”, I take it you are referring to the low-dose chemotherapy that Burzynski uses ?

Dr. Adamson, do you know what a “hack” is ?
——————————————————————
In regards to the Merritt’s, the article has:
——————————————————————
“The couple say that Burzynski misled them about the type of treatment that would be offered, as well as the cost”

My questions about the Merritt’s are:

1. Where is their complaint to the Texas Medical Board ?

2. Where is their lawsuit ? Couldn’t they find an attorney to take their case pro bono ?
——————————————————————
The article continues:
——————————————————————
“Yet even Jaffe has acknowledged that the trial — now in its 17th year — was more about politics than science”

“In his 2008 memoirs, Galileo’s Lawyer, Jaffe called it “a joke.””

“”It was all an artifice, a vehicle we and the FDA created to legally give the patients Burzynski’s treatment,” Jaffe said“
——————————————————————
What Liz Szabo and her friends at USA TODAY fail to let the readers know, is that this only applied to one trial:
——————————————————————
Burzynski’s lawyer is obviously referring to the CAN-1 clinical trial mentioned in Burzynski’s 11/25/1997 Securities and Exchange Commission (SEC) filing [11]
——————————————————————
One trial that is retrospective is CAN-1 Clinical Trial
——————————————————————
CAN-1 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH REFRACTORY MALIGNANCIES

133 patients
——————————————————————
Clinical trial of patients treated by Dr. Burzynski through 2/23/1996
——————————————————————
FDA has indicated it will not accept data generated by this trial since it was not a wholly prospective one
——————————————————————
The article continues in the same vein:
——————————————————————
“In an interview, Burzynski said developing new drugs is complex and takes time”

“Yet the FDA has approved 108 cancer drugs since Burzynski began his trial”
——————————————————————
Ms. Szabo and “pals” conveniently “forgets” to educate their audience that Burzynski was using Fleming’s One-sample multiple testing procedure for phase II clinical trials [13], which requires that if the 1st 20 patients meet certain criteria, 20 additional patients are added [14]
——————————————————————
“Well, we cannot publish until the time is right” (laughs)

Yeah

“If you would like to publish the results of, of a
10 year survival, for instance”

Mmm

“Which we have
Nobody has over 10 year survival in
malignant brain tumor, but we do, and if you like to do it right, it takes time to prepare it, and that’s what we do now
What we publish so far
We publish numerous, uh, publications which were, interim reports when we are still continuing clinical trials
Now we are preparing, a number of publications for final reports“ [15]
——————————————————————
Then Fran Visco, president of the National Breast Cancer Coalition makes an outlandish statement, which is quoted in the article:
——————————————————————
“Fran Visco, president of the National Breast Cancer Coalition, describes the FDA’s tolerance of Burzynski as “outrageous.””

“They have put people at risk for a long time,” says Visco, an attorney and breast cancer survivor”

“That’s completely unacceptable”

“How can anyone look at these facts and believe that there is a real clinical trial going on … rather than just using the FDA and the clinical trial system to make money?”
——————————————————————
I have a suggestion for Ms. Visco

Take your hypocrisy and ask the American Cancer Society if they are still engaged in this kind of activity:

1. AMERICAN CANCER SOCIETY: More Interested In Accumulating Wealth Than Saving Lives [15]

2. National Cancer Institute and American Cancer Society: Criminal Indifference to Cancer Prevention and Conflicts of Interest [16]
——————————————————————
Then, ask the American Cancer Society, why is it that 10 years ago, estimated breast cancer deaths were expected to be 39,800 (15%), and this year it was 39,620 (14%), which is ONLY 180 LESS than 10 years ago ?
——————————————————————
Estimated Breast Cancer Deaths (Women)-USA
——————————————————————
2013☝39,620 (14%)
2012👇39,510 (14%)
2011👇39,520 (15%)
2010👇39,840 (15%)
2009👇40,170 (15%)
2008☝40,480 (15%)
2007👇40,460 (15%)
2006☝40,970 (15%)
2005👇40,410 (15%)
2004☝40,110 (15%)
2003☝39,800 (15%)
2002 – 39,600 (15%)
—————————————————————–
American Cancer Society Cancer Facts & Figures (2002-2013)
—————————————————————–
And then ask the American Cancer Society, why is it that 10 years ago, the estimated NEW breast cancer cases were expected to be 211,300 (32%), and this year it was 232,340 (29%), which is 21,340 MORE than it was 10 years ago ?
——————————————————————
Estimated New Breast Cancer (Women) – USA
——————————————————————
2013☝232,340 (29%)
2012👇226,870 (29%)
2011☝238,480 (30%)
2010☝207,090 (28%)
2009☝192,370 (27%)
2008☝182,460 (26%)
2007👇178,480 (26%)
2006☝212,920 (31%)
2005👇211,240 (32%)
2004☝215,900 (32%)
2003☝211,300 (32%)
2002_-_203,500 (31%)
—————————————————————–
American Cancer Society Cancer Facts & Figures (2002-2013)
——————————————————————
And after that, ask Susan G. Komen how much is spent on legal action to protect her brand, compared to how much is spent on breast cancer research and prevention ?
——————————————————————
Visco, the breast cancer advocate

“I do NOT know why it took YOU so long.”
——————————————————————
The article continues with:
——————————————————————
“Yet hypernatremia is one of antineoplastons’ most common side effects, known to doctors for two decades”
——————————————————————
Yet, “The Skeptics™” refuse to discuss:
——————————————————————
2/13/2013 – The frequency, cost, and clinical outcomes of hypernatremia in patients hospitalized to a comprehensive cancer center

Over 3 month period in 2006 re 3,446 patients, most of the hypernatremia (90 %) was acquired during hospital stay [19]

Division of Internal Medicine, UT MD Anderson Cancer Center, Houston, TX, USA

Department of General Internal Medicine, University of Texas MD Anderson Cancer Center

Division of Endocrinology, Mayo Clinic
——————————————————————
9/1999 – The changing pattern of hypernatremia in hospitalized children [20]

Department of Pediatrics, Texas Children’s Hospital, Baylor College of Medicine, Houston, Texas, USA
——————————————————————
So, after all that, my question for USA TODAY is, does Liz Szabo, Michael Stravato, Jerry Mosemak or Robert Hanashiro have a
journalism degree ?

Because if any of them do, the institution they obtained it from most be so proud of this piece of “fish wrap” you produced

Thank you, USA TODAY, for censoring my 18 comments

I guess you must be (“intellectual”) cowards

At least Forbes had the GRAPEFRUITS to post some of my comments
——————————————————————
You’ve just been served, INSOLENTLY
——————————————————————
USA TODAY, GONE TOMORROW
——————————————————————

======================================
REFERENCES:
======================================
[1] – 11/15/2013 – USA TODAY NEWS, NATION
Doctor accused of selling false hope to families
Liz Szabo, USA TODAY
——————————————————————
http://www.usatoday.com/story/news/nation/2013/11/15/stanislaw-burzynski-cancer-controversy/2994561/
======================================
[2] – Mayo Clinic – 1999 – report: Lisa Merritt
——————————————————————
https://www.documentcloud.org/documents/816819-mayo-clinic-1999-report.html
======================================
[3] – 2012 – former Burzynski web-site screenshots, Pg 3 of 62;
——————————————————————

Click to access burzynski_fdauntitled_promo_2012.pdf

======================================
[4] – 4/26/2013 – Burzynski: FDA requirements that cancer patients utilize more traditional cancer treatment options in order to be eligible to participate in the Company’s Antineoplaston CLINICAL TRIALS:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/04/26/burzynski-fda-requirements-that-cancer-patients-utilize-more-traditional-cancer-treatment-options-in-order-to-be-eligible-to-participate-in-the-companys-antineoplaston-clinical-trials/
======================================
[5] – 11/14/2013 – Critiquing: Why we fight for patients (Why we fight your patience) TAM 2013, TAM2013, “The Amazing Meeting” 2013 #TAM2013 http://www.theamazingmeeting.com
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/11/14/tam-2013-tam2013-tam2013-the-amazing-meeting-2013-the-amazing-meeting-httptheamazingmeeting-com-httpwww-theamazingmeeting-com/
======================================
[6] – Phenomenon – Brain Tumour Foundation of Canada
——————————————————————
http://www.braintumour.ca/1649/ask-the-expert-psuedo-progression-gbm
======================================
[7] – Pseudoprogression following chemoradiotherapy for glioblastoma multiforme
Can J Neurol Sci. 2010 Jan;37(1):36-42
——————————————————————
http://www.ncbi.nlm.nih.gov/pubmed/20169771/
======================================
[8] – 9/19/2013 – Critiquing: National Cancer Institute (NCI) at the National Institutes of Health (NIH) CancerNet “fact sheet” :
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/19/critiquing-national-cancer-institute-nci-at-the-national-institutes-of-health-nih-cancernet/
======================================
[9] – FDA Orphan Drug Designation
——————————————————————

Click to access PressRelease_12022008_BZYR(2).pdf

======================================
[10] – 11/7/2013 – Pete Cohen chats with Sonali Patil, Ph.D., Research Scientist at The Burzynski Clinic:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/11/07/pete-cohen-chats-with-sonali-patil-ph-d-research-scientist-at-the-burzynski-clinic/
======================================
[11] – 7/9/2013 – Burzynski: The Original 72 Phase II Clinical Trials:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/07/09/burzynski-the-original-72-phase-ii-clinical-trials/
======================================
[12] – 8/21/2013 – Critiquing David H. Gorski, MD, PhD, FACS http://www.sciencebasedmedicine.org/editorial-staff/david-h-gorski-md-phd-managing-editor/
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/08/21/critiquing-david-h-gorski-md-phd-facs-www-sciencebasedmedicine-orgeditorial-staffdavid-h-gorski-md-phd-managing-editor/
======================================
[13] – 2003 – pg. 94
——————————————————————

Click to access 960.pdf

======================================
[14] – 3/1982 – Biometrics 1982; 38: 143-51
——————————————————————
http://www.ncbi.nlm.nih.gov/pubmed/7082756/
======================================
[15] – 11/9/2013 – Pete Cohen chats with Dr. Stanislaw Burzynski – Interview #2:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/11/09/pete-cohen-chats-with-dr-stanislaw-burzynski-interwiew-2/
======================================
[16] – AMERICAN CANCER SOCIETY: More Interested In Accumulating Wealth Than Saving Lives
——————————————————————

Click to access acs.pdf

======================================
[17] – 9/11/2013 – National Cancer Institute and American Cancer Society: Criminal Indifference to Cancer Prevention and Conflicts of Interest:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/11/national-cancer-institute-and-american-cancer-society-criminal-indifference-to-cancer-prevention-and-conflicts-of-interest/
—————————————————————
[18] – 11/13/2013 – The War on Cancer (I don’t think it means, what you think it says it means) #Winning?
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/11/13/httpcancer-orgacsgroupscontentepidemiologysurveilancedocumentsdocumentacspc-036845-pdf/
======================================
[19] – 4/24/2013 – Burzynski: HYPERNATREMIA:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/04/24/burzynski-hypernatremia/
======================================
[20] – 9/1999 – Pediatrics. 1999 Sep;104(3 Pt 1):435-9
——————————————————————
http://www.ncbi.nlm.nih.gov/pubmed/10469766/
======================================

The War on Cancer (I don’t think it means, what you think it says it means) #Winning?

“In 1971, the ACS (American Cancer Society) aggressively campaigned President Nixon to declare the “War on Cancer,” claiming that this could be won, given increased funding for the National Cancer Institute (NCI)“

“President Nixon responded by increasing its funding by $200,000”

“This was in excess of the funding that it then received as one of 30 other National Institutes of Health”

“In so doing, President Nixon effectively created an independent status for the NCI“ [0]
——————————————————————
American Cancer Society
——————————————————————
Cancer Facts & Figures 2002-2013
——————————————————————
Expected New Cancer Cases – USA
——————————————————————
2013☝1,660,290 – (21,380 more than 2012)
2012☝1,638,910 – (42,240 more than 2011)
2011☝1,596,670 – (67,160 more than 2010)
2010☝1,529,560 – (49,810 more than 2009)
2009☝1,479,350 – (42,170 more than 2008)
2008👇1,437,180 – ( 7,740 less than 2007)
2007☝1,444,920 – (45,130 more than 2006)
2006☝1,399,790 – (26,880 more than 2005)
2005☝1,372,910 – ( 4,870 more than 2004)
2004☝1,368,030 – (33,930 more than 2003)
2003☝1,334,100 – (49,200 more than 2002)
2002 – 1,284,900
——————————————————————
Expected to Die – United States
——————————————————————
2013☝580,350_-_(3,160 more than 2012)
2012☝577,190_-_(5,240 more than 2011)
2011☝571,950_-_(2,460 more than 2010)
2010☝569,490_-_(7,150 more than 2009)
2009👇562,340_-_(3,310 less than 2008)
2008☝565,650_-_(6,000 more than 2007)
2007👇559,650_-_(5,180 less than 2006)
2006👇564,830_-_(5,450 less than 2005)
2005☝570,280_-_(6,580 more than 2004
2004☝563,700_-_(7,200 more than 2003)
2003☝556,500_-_(6,000 more than 2002)
2002_-_555,500
——————————————————————
Deaths – United States of America
——————————————————————
2013 – almost 1,600 a day
2012 – 1,500+ a day
2011 – 1,500+ a day
2010 – 1,500+ a day
2009 – 1,500+ a day
2008 – 1,500+ a day
2007 – 1,500+ a day
2006 – 1,500+ a day
2005 – 1,500+ a day
2004 – 1,500+ a day
2003 – 1,500+ a day
======================================
Estimated Childhood Cancer Deaths (0-14 years)
——————————————————————
2013👇1, 310
2012☝1,340
2011👇1,320
2010👇1,340
2009👇1,380
2008👇1,490
2007👇1,545
2006👇1,560
2005☝1,585
2004☝1,510
2003☝1,500
2002 – 1,400
——————————————————————
Estimated New Childhood Cancer (0-14 years)
——————————————————————
2013👇11,630
2012☝12,060
2011☝11,210
2010👇10,700
2009 – 10,730
2008☝10,730
2007☝10,400
2006👇9,500
2005☝9,510
2004☝9,200
2003👇9,000
2002 – 9,100
======================================
Estimated Brain and other nervous system Cancer Deaths (Women)
——————————————————————
2013☝6,150 (2%)
2012☝5,980 (2%)
2011👇5,670 (2%)
2010☝5,720 (2%)
2009👇5,590 (2%)
2008☝5,650 (2%)
2007☝5,590 (2%)
2006☝5,560 (2%)
2005👇5,480 (2%)
2004👇5,490 (2%)
2003👇5,800 (2%)
2002 – 5,900 (2%)
======================================
Estimated All Cancer Deaths (Women)
——————————————————————
2013👇273,430 (100%)
2012☝275,370 (100%)
2011☝271,520 (100%)
2010☝270,290 (100%)
2009👇269800 (100%)
2008☝271,530 (100%)
2007👇270,100 (100%)
2006👇273,560 (100%)
2005☝275,000 (100%)
2004☝272,810 (100%)
2003☝270,600 (100%)
2002_-_267,300 (100%)
——————————————————————
Estimated Lung and bronchus Cancer Deaths (Women)
——————————————————————
2013👇72,220 (26%)
2012☝72,590 (26%)
2011☝71,340 (26%)
2010☝71,080 (26%)
2009👇70,490 (26%)
2008☝71,030 (26%)
2007👇70,880 (26%)
2006👇72,130 (26%)
2005☝73,020 (27%)
2004👇68,510 (25%)
2003☝68,800 (25%)
2002 – 65,700 (25%)
——————————————————————
Estimated Breast Cancer Deaths (Women)
——————————————————————
2013☝39,620 (14%)
2012👇39,510 (14%)
2011👇39,520 (15%)
2010👇39,840 (15%)
2009👇40,170 (15%)
2008☝40,480 (15%)
2007👇40,460 (15%)
2006☝40,970 (15%)
2005👇40,410 (15%)
2004☝40,110 (15%)
2003☝39,800 (15%)
2002 – 39,600 (15%)
——————————————————————
Estimated Colon and rectum Cancer Deaths (Women)
——————————————————————
2013👇24,530 (9%)
2012☝25,220 (9%)
2011👇24,130 (9%)
2010👇24,790 (9%)
2009👇24,680 (9%)
2008👇25,790 (9%)
2007👇26,180 (10%)
2006👇27,300 (10%)
2005👇27,750 (10%)
2004👇28,410 (10%)
2003 – 28,800 (11%)
2002 – 28,800 (11%)
——————————————————————
Estimated Pancreas Cancer Deaths (Women)
——————————————————————
2013☝18,970 (7%)
2012☝18,540 (7%)
2011☝18,300 (7%)
2010☝18,030 (7%)
2009☝17,210 (6%)
2008☝16,790 (6%)
2007☝16,530 (6%)
2006☝16,210 (6%)
2005☝15,980 (6%)
2004☝15,830 (6%)
2003☝15,300 (16%)
2002 – 15,200 (16%)
——————————————————————
Estimated Ovary Cancer Deaths (Women)
——————————————————————
2013👇14,030 (5%)
2012☝15,500 (6%)
2011☝15,460 (6%)
2010👇13,850 (5%)
2009👇14,600 (5%)
2008☝15,520 (6%)
2007👇15,280 (6%)
2006👇15,310 (6%)
2005☝16,210 (6%)
2004☝16,090 (6%)
2003☝14,300 (5%)
2002 – 13,900 (5%)
——————————————————————
Estimated Leukemia Deaths (Women)
——————————————————————
2013☝10,060 (4%)
2012☝10,040 (4%)
2011👇9,040 (3%)
2010👇9,180 (3%)
2009☝9,280 (3%)
2008👇9,250 (3%)
2007👇9,470 (4%)
2006👇9,810 (4%)
2005👇10,030 (4%)
2004☝10,310 (4%)
2003☝9,800 (4%)
2002 – 9,600 (4%)
——————————————————————
Estimated Non-Hodgkin lymphoma Deaths (Women)
——————————————————————
2013👇8,430 (3%)
2012👇8,620 (3%)
2011☝9,570 (4%)
2010👇9,500 (4%)
2009☝9,670 (4%)
2008☝9,370 (3%)
2007☝9,060 (3%)
2006👇8,840 (3%)
2005☝9,050 (3%)
2004👇9,020 (3%)
2003👇11,200 (4%)
2002 – 11,700 (4%)
——————————————————————
Estimated Uterine corpus Cancer Deaths (Women)
——————————————————————
2013☝8,190 (3%)
2012👇8,010 (3%)
2011☝8,120 (3%)
2010☝7,950 (3%)
2009☝7,780 (3%)
2008☝7,470 (3%)
2007☝7,400 (3%)
2006☝7,350 (3%)
2005☝7,310 (3%)
2004☝7,090 (3%)
2003☝6,800 (3%)
2002 – 6,600 (2%)
——————————————————————
Estimated Liver and intrahepatic bile duct Cancer Deaths (Women)
——————————————————————
2013☝6,780 (2%)
2012☝6,570 (2%)
2011☝6,330 (2%)
2010☝6,190 (2%)
2009☝6,070 (2%)
2008☝5,840 (2%)
2007 – 5,500 (2%)
2006
2005
2004
2003
2002
——————————————————————
Estimated Multiple myeloma Cancer Deaths (Women)
——————————————————————
2013
2012
2011
2010
2009
2008
2007
2006👇5,630 (2%)
2005 – 5,640 (2%)
2004☝5,640 (2%)
2003☝5,500 (2%)
2002 – 5,300 (2%)
======================================
Estimated New Cancer All (Women)
——————————————————————
2013☝805,500 (100%)
2012☝790,740 (100%)
2011☝774,370 (100%)
2010☝739,940 (100%)
2009☝713,220 (100%)
2008☝692,000 (100%)
2007👇678,060 (100%)
2006☝679,510 (100%)
2005👇662,870 (100%)
2004☝668,470 (100%)
2003☝658,800 (100%)
2002_-_647,400 (100%)
——————————————————————
Estimated New Breast Cancer (Women)
——————————————————————
2013☝232,340 (29%)
2012👇226,870 (29%)
2011☝238,480 (30%)
2010☝207,090 (28%)
2009☝192,370 (27%)
2008☝182,460 (26%)
2007👇178,480 (26%)
2006☝212,920 (31%)
2005👇211,240 (32%)
2004☝215,900 (32%)
2003☝211,300 (32%)
2002_-_203,500 (31%)
——————————————————————
Estimated New Lung and bronchus Cancer (Women)
——————————————————————
2013☝110,110 (14%)
2012☝109,690 (14%)
2011☝106,070 (14%)
2010☝105,770 (14%)
2009☝103,350 (14%)
2008☝100,330 (14%)
2007☝98,620 (15%)
2006☝81,770 (12%)
2005👇79,560 (12%)
2004☝80,660 (12%)
2003☝80,100 (12%)
2002 – 79,200 (12%)
——————————————————————
Estimated New Colon and rectum Cancer (Women)
——————————————————————
2013👇69,140 (9%)
2012☝70,040 (9%)
2011👇69,360 (9%)
2010👇70,480 (10%)
2009👇71,380 (10%)
2008👇71,560 (10%)
2007👇74,630 (11%)
2006☝75,810 (11%)
2005☝73,470 (11%)
2004👇73,320 (11%)
2003👇74,700 (11%)
2002 – 75,700 (12%)
——————————————————————
Estimated New Uterine corpus Cancer (Women)
——————————————————————
2013☝49,560 (6%)
2012☝47,130 (6%)
2011☝46,470 (6%)
2010☝43,470 (6%)
2009☝42,160 (6%)
2008☝41,100 (6%)
2007👇39,080 (6%)
2006☝41,200 (6%)
2005☝40,880 (6%)
2004👇40,320 (6%)
2003☝41,00 (6%)
2002 – 39,300 (6%)
——————————————————————
Estimated New Thyroid Cancer (Women)
——————————————————————
2013☝45,310 (6%)
2012☝43,210 (5%)
2011☝36,550 (5%)
2010☝33,930 (5%)
2009👇27,200 (4%)
2008☝28,410 (4%)
2007☝25,480 (4%)
2006☝22,590 (3%)
2005☝19,190 (3%)
2004☝17,640 (3%)
2003☝16,300 (3%)
2002 – 15,800 (2%)
——————————————————————
Estimated New Non-Hodgkin lymphoma (Women)
——————————————————————
2013☝32,140 (4%)
2012☝31,970 (4%)
2011☝30,300 (4%)
2010☝30,160 (4%)
2009👇29,990 (4%)
2008☝30,660 (4%)
2007☝28,990 (4%)
2006☝28,190 (4%)
2005☝27,320 (4%)
2004☝25,520 (4%)
2003👇25,100 (4%)
2002 – 25,700 (4%)
——————————————————————
Estimated New Melanoma of the skin Cancer (Women)
——————————————————————
2013👇31,630 (4%)
2012☝32,000 (4%)
2011☝30,220 (4%)
2010👇29,260 (4%)
2009☝29,640 (4%)
2008☝27,530 (4%)
2007👇26,030 (4%)
2006☝27,930 (4%)
2005☝26,000 (4%)
2004☝25,200 (4%)
2003☝24,300 (3%)
2002 – 23,500 (4%)
——————————————————————
Estimated New Kidney and renal pelvis Cancer (Women)
——————————————————————
2013☝24,720 (3%)
2012☝24,520 (4%)
2011☝23,800 (3%)
2010☝22,870 (3%)
2009☝22,330 (3%)
2008☝21,260 (3%)
2007 – 19,600 (3%)
2006
2005
2004
2003
2002
——————————————————————
Estimated New Pancreas Cancer (Women)
——————————————————————
2013☝22,489 (3%)
2012👇21,830 (3%)
2011☝21,980 (3%)
2010☝21,770 (3%)
2009 21,420 (3%)
2008
2007
2006☝16,580 (2%)
2005👇16,080 (2%)
2004☝16,120 (2%)
2003☝15,800 (2%)
2002 – 15,600 (2%)
——————————————————————
Estimated New Ovary Cancer (Women)
——————————————————————
2013👇22,240 (3%)
2012☝22,280 (3%)
2011☝21,990 (3%)
2010☝21,880 (3%)
2009👇21,550 (3%)
2008👇21,650 (3%)
2007☝22,430 (3%)
2006👇20,180 (3%)
2005👇22,220 (3%)
2004☝25,580 (4%)
2003☝25,400 (4%)
2002 – 23,300 (4%)
——————————————————————
Estimated New Leukemia (Women)
——————————————————————
2013
2012
2011
2010
2009
2008👇19,090 (3%)
2007 – 19,440 (3%)
2006
2005
2004
2003
2002
——————————————————————
Estimated New Urinary bladder Cancer (Women)
——————————————————————
2013
2012
2011
2010
2009
2008
2007
2006☝16,730 (2%)
2005☝16,200 (2%)
2004☝15,600 (2%)
2003 – 15,200 (2%)
2002 – 15,200 (2%)
======================================
Estimated All Cancer Deaths (Men)
——————————————————————
2013☝306,920 (100%)
2012☝301,820 (100%)
2011☝300,430 (100%)
2010☝299,200 (100%)
2009👇292,540 (100%)
2008☝294,120 (100%)
2007👇289,550 (100%)
2006👇291,270 (100%)
2005☝295,280 (100%)
2004☝290,890 (100%)
2003👇285,900 (100%)
2002_-_288,200 (100%)
——————————————————————
Estimated Lung and bronchus Deaths (Men)
——————————————————————
2013👇87,260 (28%)
2012☝87,750 (29%)
2011👇85,600 (28%)
2010👇86,220 (29%)
2009👇88,900 (30%)
2008☝98,810 (31%)
2007👇89,510 (31%)
2006👇90,330 (31%)
2005👇90,490 (31%)
2004☝91,930 (32%)
2003👇88,400 (31%)
2002 – 89,200 (31%)
——————————————————————
Estimated Prostate Cancer Deaths (Men)
——————————————————————
2013☝29,720 (10%)
2012👇28,170 (9%)
2011☝33,720 (11%)
2010☝32,050 (11%)
2009👇27,360 (9%)
2008☝28,660 (10%)
2007👇27,050 (9%)
2006👇27,350 (9%)
2005☝30,350 (10%)
2004☝29,500 (10%)
2003👇28,900 (10%)
2002 – 30,200 (11%)
——————————————————————
Estimated Colon and rectum Cancer Deaths (Men)
——————————————————————
2013👇26,300 (9%)
2012☝26,470 (9%)
2011👇25,250 (8%)
2010☝26,580 (9%)
2009☝25,240 (9%)
2008👇24,260 (8%)
2007👇26,000 (9%)
2006👇27,870 (10%)
2005☝28,540 (10%)
2004☝28,320 (10%)
2003☝28,300 (10%)
2002 – 27,800 (10%)
——————————————————————
Estimated Pancreas Cancer Deaths (Men)
——————————————————————
2013☝19,480 (6%)
2012👇18,850 (6%)
2011☝19,360 (3%)
2010☝18,770 (6%)
2009☝18,030 (6%)
2008☝17,500 (6%)
2007☝16,840 (6%)
2006☝16,090 (6%)
2005☝15,820 (5%)
2004☝15,440 (5%)
2003☝14,700 (5%)
2002 – 14,500 (5%)
——————————————————————
Estimated Liver and intrahepatic bile duct Cancer Deaths (Men)
——————————————————————
2013☝14,890 (5%)
2012☝13,980 (5%)
2011☝13,260 (4%)
2010☝12,720 (4%)
2009👇12,090 (4%)
2008☝12,570 (4%)
2007☝11,280 (4%)
2006☝10,840 (4%)
2005☝10,330 (3%)
2004☝9,450 (3%)
2003☝9,200 (3%)
2002 – 8,900 (3%)
——————————————————————
Estimated Leukemia Deaths (Men)
——————————————————————
2013☝13,660 (4%)
2012☝13,500 (4%)
2011☝12,740 (4%)
2010☝12,660 (4%)
2009☝12,590 (4%)
2008☝12,460 (4%)
2007👇12,320 (4%)
2006👇12,470 (4%)
2005👇12,540 (4%)
2004☝12,990 (5%)
2003 – 12,100 (4%)
2002 – 12,100 (4%)
——————————————————————
Estimated Esophagus Cancer Deaths (Men)
——————————————————————
2013☝12,220 (4%)
2012☝12,040 (4%)
2011☝11,910 (4%)
2010☝11,650 (4%)
2009☝11,490 (4%)
2008☝11,250 (4%)
2007☝10,900 (4%)
2006☝10,730 (4%)
2005☝10,530 (4%)
2004☝10,250 (4%)
2003☝9,900 (4%)
2002 – 9,600 (3%)
——————————————————————
Estimated Urinary bladder Cancer Deaths (Men)
——————————————————————
2013☝10,820 (4%)
2012👇10,510 (3%)
2011☝10,670 (4%)
2010☝10,410 (3%)
2009☝10,180 (3%)
2008☝9,950 (3%)
2007☝9,630 (3%)
2006☝8,990 (3%)
2005☝8,970 (3%)
2004☝8,780 (3%)
2003 – 8,600 (3%)
2002 – 8,600 (3%)
——————————————————————
Estimated Non-Hodgkin lymphoma Deaths (Men)
——————————————————————
2013☝10,590 (3%)
2012☝10,320 (3%)
2011👇9,750 (3%)
2010☝10,710 (4%)
2009☝9,830 (3%)
2008☝9,790 (3%)
2007👇9,600 (3%)
2006👇10,000 (3%)
2005👇10,150 (3%)
2004👇10,390 (4%)
2003👇12,200 (4%)
2002 – 12,700 (5%)
——————————————————————
Estimated Kidney and renal pelvis Cancer Deaths (Men)
——————————————————————
2013☝8,780 (3%)
2012☝8,650 (3%)
2011☝8,270 (3%)
2010☝8,210 (3%)
2009☝8,160 (3%)
2008☝8,100 (3%)
2007👇8,080 (3%)
2006☝8,130 (3%)
2005☝8,020 (3%)
2004☝7,870 (3%)
2003☝7,409 (3%)
2002 – 7,200 (3%)
======================================
Estimated New Cancer All (Men)
——————————————————————
2013☝854,790 (100%)
2012☝848,170 (100%)
2011☝822,300 (100%)
2010☝789,620 (100%)
2009☝766,130 (100%)
2008👇745,180 (100%)
2007☝766,860 (100%)
2006☝720,280 (100%)
2005☝710,040 (100%)
2004☝699,560 (100%)
2003☝675,300 (100%)
2002_-_637,500 (100%)
——————————————————————
Estimated New Prostate Cancer (Men)
——————————————————————
2013👇238,590 (28%)
2012☝241,470 (29%)
2011☝240,890 (29%)
2010☝217,730 (28%)
2009☝192,280 (25%)
2008👇186,320 (25%)
2007👇218,890 (29%)
2006☝234,460 (33%)
2005☝232,090 (33%)
2004☝230,110 (33%)
2003☝220,900 (33%)
2002_-_189,000 (30%)
——————————————————————
Estimated New Lung and bronchus Cancer (Men)
——————————————————————
2013☝118,080 (14%)
2012☝116,470 (14%)
2011👇115,060 (14%)
2010☝116,750 (15%)
2009☝116,090 (15%)
2008👇114,690 (15%)
2007☝114,760 (15%)
2006👇92,700 (13%)
2005👇93,010 (13%)
2004☝93,110 (13%)
2003☝91,800 (14%)
2002 – 90,200 (14%)
——————————————————————
Estimated New Colon and rectum Cancer (Men)
——————————————————————
2013☝73,680 (13%)
2012☝73,420 (9%)
2011👇71,850 (9%)
2010👇72,090 (9%)
2009👇75,590 (10%)
2008👇77,250 (10%)
2007☝79,130 (10%)
2006☝72,800 (10%)
2005👇71,820 (10%)
2004☝73,620 (11%)
2003☝72,800 (11%)
2002 – 72,600 (11%)
——————————————————————
Estimated New Urinary bladder Cancer (Men)
——————————————————————
2013👇54,610 (6%)
2012☝55,600 (7%)
2011👇52,020 (6%)
2010👇52,760 (7%)
2009☝52,810 (7%)
2008☝51,230 (7%)
2007☝50,040 (7%)
2006👇44,690 (6%)
2005☝47,010 (7%)
2004☝44,640 (6%)
2003☝42,200 (6%)
2002 – 41,500 (7%)
——————————————————————
Estimated New Melanoma of the skin Cancer (Men)
——————————————————————
2013☝45,060 (5%)
2012☝44,250 (5%)
2011☝40,010 (5%)
2010👇38,870 (5%)
2009☝39,080 (5%)
2008☝34,950 (5%)
2007👇33,910 (4%)
2006☝34,260 (5%)
2005☝33,580 (5%)
2004 – 29,900 (4%)
2003👇29,900 (4%)
2002 – 30,100 (5%)
——————————————————————
Estimated New Kidney and renal pelvis Cancer (Men)
——————————————————————
2013☝40,430 (5%)
2012☝40,250 (5%)
2011☝37,120 (5%)
2010👇35,370 (4%)
2009☝35,430 (5%)
2008☝33,130 (4%)
2007☝31,590 (4%)
2006☝24,650 (3%)
2005☝22,490 (3%)
2004☝22,080 (3%)
2003☝19,500 (3%)
2002 – 19,100 (3%)
——————————————————————
Estimated New Non-Hodgkin lymphoma (Men)
——————————————————————
2013👇37,600 (4%)
2012☝38,160 (4%)
2011☝36,060 (4%)
2010👇35,380 (4%)
2009☝35,990 (5%)
2008☝35,450 (5%)
2007☝34,200 (4%)
2006☝30,680 (4%)
2005☝29,070 (4%)
2004☝28,850 (4%)
2003☝28,300 (4%)
2002 – 28,200 (4%)
——————————————————————
Estimated New Oral cavity and pharynx Cancer (Men)
——————————————————————
2013☝29,620 (3%)
2012☝28,540 (3%)
2011☝27,710 (3%)
2010☝25,420 (3%)
2009👇25,240 (3%)
2008☝25,310 (3%)
2007☝24,180 (3%)
2006☝20,180 (3%)
2005☝19,100 (3%)
2004☝18,550 (3%)
2003👇18,200 (3%)
2002 – 18,900 (3%)
——————————————————————
Estimated New Leukemia (Men)
——————————————————————
2013☝27,880 (3%)
2012☝26,830 (3%)
2011☝25,320 (3%)
2010👇24,690 (3%)
2009☝25,630 (3%)
2008☝25,180 (3%)
2007☝24,800 (3%)
2006☝20,000 (3%)
2005☝19,640 (3%)
2004☝19,020 (3%)
2003☝17,900 (3%)
2002 – 17,600 (3%)
——————————————————————
Estimated New Pancreas Cancer (Men)
——————————————————————
2013☝22,740 (3%)
2012☝22,090 (3%)
2011☝22,050 (3%)
2010☝21,370 (3%)
2009☝21,050 (3%)
2008👇18,770 (3%)
2007☝18,830 (2%)
2006☝17,150 (2%)
2005☝16,109 (2%)
2004☝15,740 (2%)
2003☝14,900 (2%)
2002 – 14,700 (2%)
======================================

——————————————————————
American Cancer Society
——————————————————————
Cancer Facts & Figures
======================================
REFERENCES:
======================================
[0] – AMERICAN CANCER SOCIETY

More Interested In Accumulating Wealth Than Saving Lives

Samuel S. Epstein, M.D.

Emeritus professor Environmental and Occupational Medicine

University of Illinois School of Public Health

and

Chairman, The Cancer Prevention Coalition
——————————————————————
http://www.wnho.net/acs.pdf
======================================
2013
——————————————————————

Click to access acspc-036845.pdf

——————————————————————

Click to access acspc-036845.pdf

——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/index
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013
======================================
2012
——————————————————————

Click to access acspc-031941.pdf

——————————————————————

Click to access acspc-031941.pdf

——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2012/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2012/index
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2012
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2012
======================================
2011
——————————————————————

Click to access acspc-029771.pdf

——————————————————————

Click to access acspc-029771.pdf

——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2011
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2011
======================================
2010
——————————————————————

Click to access acspc-024113.pdf

——————————————————————

Click to access acspc-024113.pdf

——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2010/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2010/index
======================================
2009
——————————————————————

Click to access 500809webpdf.pdf

——————————————————————

Click to access 500809webpdf.pdf

——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2009/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2009/index
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2009
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2009
======================================
2008
——————————————————————

Click to access worldcancer.pdf

——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2008/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2008/index
——————————————————————
http://cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
======================================
2007
——————————————————————

Click to access caff2007pwsecuredpdf.pdf

——————————————————————

Click to access caff2007pwsecuredpdf.pdf

——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2007/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2007/index
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2007
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2007
======================================
2006
——————————————————————

Click to access caff2006pwsecuredpdf.pdf

——————————————————————

Click to access caff2006pwsecuredpdf.pdf

——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2006
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2006
======================================
2005
——————————————————————

Click to access caff2005f4pwsecuredpdf.pdf

——————————————————————

Click to access caff2005f4pwsecuredpdf.pdf

——————————————————————
http://cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2005
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2005
======================================
2004
——————————————————————

Click to access CancerRates2004.pdf

======================================
2003
——————————————————————

Click to access 2003_ACS_Cancer_Facts.pdf

======================================
2002
——————————————————————

Click to access CancerFacts&Figures2002.pdf

======================================

National Cancer Institute and American Cancer Society: Criminal Indifference to Cancer Prevention and Conflicts of Interest

[1] – 1998 – According to Epstein, “Dr. Samuel Broder, National Cancer Institute (NCI) director from 1989 to 1995, frankly admitted, in a 1998 Washington Post interview:

‘the NCI has become what amounts to a government pharmaceutical company.’

“Taxpayers have funded R & D and expensive clinical trials for over two-thirds of cancer drugs on the market”

These drugs are given, with exclusive rights, to the industry, which sells them at inflated prices.”
====================================
REFERENCES:
====================================
[1] – 1998
——————————————————————
http://www.naturalnews.com/032700_National_Cancer_Institute_Dr_Samuel_Epstein.html
——————————————————————
http://m.naturalnews.com/news/032700_National_Cancer_Institute_Dr_Samuel_Epstein.html
====================================
[2] – 7/26/2000 – The Politics of Cancer, Vol. 284 No. 4, July 26, 2000, Samuel S. Epstein, MD, University of Illinois, Chicago
——————————————————————
http://jama.jamanetwork.com/Mobile/issue.aspx?journalid=67&issueid=4745&direction=P
——————————————————————
http://www.preventcancer.com/publications/pdf/letter_JAMA_july262000.htm
====================================
[3] – AMERICAN CANCER SOCIETY, More Interested In Accumulating Wealth Than Saving Lives (130 pgs.), Samuel S. Epstein, M.D., Emeritus professor, Environmental and Occupational Medicine University of Illinois School of Public Health and Chairman, The Cancer Prevention Coalition
AMERICAN CANCER SOCIETY DEBATES EPSTEIN, 19 Corporate Crime Reporter 20(1), May.10, 2005 (Pg. 129)
——————————————————————

Click to access acs.pdf

——————————————————————
http://www.karlloren.com/biopsy/p60.htm
====================================

Critiquing: American Cancer Society – Antineoplaston Therapy

[1] – The American Cancer Society Antineoplaston Therapy Overview claims:
=====================================
=====================================
” In other words, there is no convincing evidence showing that antineoplastons actually work“
=====================================
=====================================
====================================
Interestingly, the above Overview does NOT provide any specific citation(s), reference(s), or link(s) to support this claim
——————————————————————
[2] – 10/4/1991 – Five doctors (3 from the Cancer Therapy Evaluation Branch (CTEP); including the Head of the Quality Assurance and Compliance Section, Regulatory Affairs Branch, Cancer Therapy Evaluation Program, Department of Health &Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, and 2 invited consultants; including one from the National Institutes of Health (NIH) Clinical Center) visited the offices of Dr. Stanislaw R. Burzynski
——————————————————————
[3] – 10/31/1991 – Michael A. Friedman, M.D. Associate Director, Cancer Therapy Evaluation Program (CTEP), Department of Health &Human Services, National Institutes of Health, National Cancer Institute, sent a one page Memorandum to Bruce A. Chabner, M.D., Director, Division of Cancer Treatment, which stated, in part:

“I thought you would be interested in this for several reasons:”

“3. Antineoplastons deserve a closer look”

“It turns out that the agents are well defined, pure chemical entities“
=======================================
=======================================
“The human brain tumor responses are real”

=======================================
[4] – 11/15/1991 – Michael J. Hawkins, M.D., Chief, Investigational Drug Branch, Department of Health &Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, sent a 7 page letter to Decision Network, which stated, in part, on page one:
=======================================
=======================================
“It was the opinion of the site visit team that antitumor activity was documented in this best case series … “

=======================================
[5] – 12/2/91 – NCI (National Cancer Institute), Decision Network Report on Antineoplastons, states in part, on page 11:
=======================================
=======================================
“The site visit team determined that antitumor activity was documented in this best case series … “

=======================================
[6] – CANCER FACTS
National Cancer Institute • National Institutes of Health Department of Health and Human Services, Antineoplastons, pg. 1
=======================================
=======================================
“The reviewers of this series found evidence of antitumor activity … “

=======================================
[7] – Page 1 of 6, BlueCross BlueShield of Alabama, Antineoplaston Cancer Therapy, Policy #: 280, Category: Medicine, states, in part, on page 2 of 6:

Key Points:
=======================================
=======================================
“The reviewers of this series found evidence of antitumor activity … “
=======================================
=======================================
[8] – ANTINEOPLASTON THERAPY, HS-183, pg. 2
=======================================
=======================================
“After the reviewers found some evidence of antitumor activity … “
=======================================
=======================================
These facts indicate to me that the American Cancer Society’s claim about “antineoplastons”, is “debatable”

Maybe they should have learned how to use the Freedom of Information Act (FOIA)
=======================================
REFERENCES:
=======================================
[1]
——————————————————————
http://m.cancer.org/treatment/treatmentsandsideeffects/complementaryandalternativemedicine/pharmacologicalandbiologicaltreatment/antineoplaston-therapy
=======================================
[6]
——————————————————————

Click to access Antineoplastons.pdf

=======================================
[7]
——————————————————————

Click to access 280.pdf

=======================================
[8]
——————————————————————

Click to access HS183_Antineoplaston_Therapy.pdf

=======================================